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vAbstract
Allergic asthma is a chronic inflammatory disease, in which sensitisation occurs via the respiratory
tract. It involves T-helper(Th)2-lymphocytes, mast cells and eosinophils, leading to physiological
and structural changes in the lung, i.e. airway hyper responsiveness, restricted airflow and
airway remodelling. The hygiene hypothesis points out that the absence of Th1-favouring
signals, e.g. bacterial pathogen associated-molecular patterns (PAMPs), promotes allergic
sensitisation. PAMPs are sensed by a variety of receptors of the innate and adaptive immune
response, e.g. toll-like receptors (TLR). TLR2 is expressed on dendritic cells, which are believed
to be one of the key players of initiating and maintaining immune responses. Furthermore,
dendritic cells modulate immunity either to Th1- or Th2-responses, or induction of tolerance.
Mycoplasma-induced immune responses are mediated via TLR2-heterodimers and prevent a
subsequent allergic sensitisation.
In this thesis, mouse models of sensitisation towards Timothy grass pollen allergens were devel-
oped, which reflect the acute, sub-chronic and chronic phase of allergic asthma. Mechanisms were
clarified which led to prevention or augmentation of allergic inflammation, airway hyper respon-
siveness and airway remodelling when the Mycoplasma-derived TLR-agonist BPPcysMPEG was
administered locally. Furthermore, synergistic effects of a combination of the TLR-agonist and
the Th1-cytokine interferon (IFN)-γ were investigated and compared to the standard therapeutic
dexamethasone.
The experimental models developed in this thesis resemble clinical signs of human allergic asthma,
the grass pollen allergen used is of clinical relevance, and chronic sensitisation via the respiratory
tract and structural changes in the lung could be reflected. Additionally, dexamethasone
treatment showed comparable effects as observed in patients.
It could be demonstrated, that acute-phase allergic asthma is prevented and therapeutically
intervened by BPPcysMPEG/IFN-γ-treatment. Also a therapeutic intervention of the sub-
chronic phase was sufficient to reduce asthma symptoms. In a model of chronic respiratory
sensitisation, prevention of allergic airway inflammation and airway remodelling could be achieved
by the combinatory treatment as well as solely with the TLR2-agonist.
These beneficial effects on allergic asthma seem to be unrelated to a Th2/Th1-shift or induction
of tolerance, but rather to impacts on general T-cell function. This overall effect makes this
pharmacological approach promising for the prevention and treatment of diseases related to
disturbed T-cell function, as asthma and inflammatory bowel disease.
Keywords: Toll-like receptor agonists, murine asthma models, grass pollen allergens
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Zusammenfassung
Das allergische Asthma bronchiale ist eine chronische entzündliche Erkrankung der Lunge, in
der die Sensibilisierung über die Atemwege erfolgt. Das Zusammenspiel von T-Helfer-Typ-
2(Th2)-Lymphozyten, eosinophilen Granulozyten und Mastzellen verursacht physiologische und
strukturelle Veränderungen der Lunge, wie Atemwegshyperreagibilität, eingeschränkten Atem-
fluss und Umbau der Atemwege. Die Hygienehypothese bringt die allergische Sensibilisierung mit
verminderten Th1-induzierenden Signalen, wie zum Beispiel bakteriellen pathogen-assoziierten
molekularen Mustern (PAMP,) in Verbindung. Bakterielle PAMPs werden von einer Vielzahl
von Rezeptoren der angeborenen und adaptiven Immunantwort erkannt, wie z.B. Toll-like
Rezeptoren (TLR). Der TLR2 ist auf Dendritischen Zellen exprimiert, denen eine grundlegende
Rolle in der Einleitung und Aufrechterhaltung von Immunantworten beigemessen wird. Desweit-
eren modulieren Dendritische Zellen die Immunantwort in Richtung Th1, Th2 oder Toleranz.
Durch Mycoplasmen ausgelöste Immunantworten werden über den TLR2 vermittelt und wirken
präventiv auf eine nachfolgende Sensibilisierung.
In dieser Arbeit wurden Wiesen-Lieschgras-Allergen-induzierte Mausmodelle entwickelt, die
sowohl die akute, die sub-chronische als auch die chronische Phase des Asthmas nachbilden.
Wirkmechanismen einer lokalen präventiven oder therapeutischen Behandlung mit dem aus
Mycoplasma-generierten TLR-Agonisten BPPcysMPEG auf die Erkrankung wurden beschrieben,
synergistische Effekte der kombinatorischen Behandlung mit dem TLR-Agonisten und dem
Th1-Zytokin Interferon(IFN)-γ untersucht und mit dem Standardtherapeutikum Dexamethason
verglichen.
Die in dieser Arbeit entwickelten Mausmodelle weisen eine hohe Vergleichbarkeit mit dem
allergischen Asthma des Menschen auf. Die Behandlung mit Dexamethason zeigte vergleichbare
Wirkung wie im Patienten. Das verwendete Gräserpollenallergen besitzt hohe klinische Relevanz,
und auch eine Sensibilisierung über die Atemwege konnte nachgestellt werden. Es konnte gezeigt
werden, dass das allergische Asthma präventiv und therapeutisch mit BPPcysMPEG/IFN-γ
beeinflusst werden kann.
Es gab klare Hinweise darauf, dass die positive Beeinflussung des allergischen Asthmas dabei
nicht durch eine Verschiebung der Th2-Antwort in Richtung Th1 oder die Induktion von Toleranz
verursacht werden, sondern eher durch Beeinflussung der T-Zell-Funktion. Der generelle Effekt
weist die Behandlung als einen vielversprechenden neuen Ansatz der Prävention und Therapie von
Erkrankungen aus, die mit fehlgeleiteter T-Zell-Funktion in Verbindung stehen, wie allergisches
Asthma oder entzündliche Darmerkrankungen.
Schlagworte: Toll-like Rezeptoragonisten, murine Asthmamodelle, Graspollenallergene
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1 Introduction
1.1 Allergic asthma bronchiale
If urgent action is not taken, the threat of deaths caused by asthma might increase by
almost 20% in the next ten years [1]. Therefore, potent pharmaceuticals are needed.
According to the World Health Organization, approximately 300 million humans worldwide
suffer from allergic asthma. For the year 2005 255,000 deaths by asthma are estimated in
WHO member states [1]. By now only few causative therapies exist. Most patients need a
lifelong medicamentation, which influences the quality of life and causes enormous costs.
Basically, an allergic vs. a non-allergic genesis of asthma is distinguished. In allergic
asthma, one or several allergens can be verified, which cause inflammation of the airways.
This is promoted by risk factors as atopy, existing allergic rhinitis or cigarette smoking [2].
In allergic asthma different clinical signs can be observed in patients, e.g. persistent
eosinophilic inflammation, airway hyper reactivity towards allergens and unspecific stimuli,
such as cold air or cigarette smoke, and structural changes in the airway architecture.
1.1.1 The hygiene hypothesis
The hygiene hypothesis relates the increasing prevalence and incidence of allergic diseases
in the so called Western world with a cease in Th1-immune responses inducing triggers, e.g.
bacterial infections [3, 4, 5]. Bacterial infections are reduced due to a less frequent direct
confrontation to bacteria, but also indirectly due to a decrease in the number of siblings
[6, 7]. Interestingly, farmers´children are much less likely to develop an allergic disorder
during life than children from the same geographical region. This is again correlated to
Th1-triggers in the direct environment [6].
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The onset of allergic asthma is believed to be related to a perturbation in the Th1/Th2-
balance. As a newborn, children possess a more Th2-characterised pattern of immune
responses, and subsequent Th1-triggering might balance the immune system. Th1-
and Th2-responses differ in their cytokine pattern: the characteristic cytokine in Th1-
mediated responses, e.g. bacterial infections, is Interferon-γ (IFN-γ). The Th2-response
is characterised by Interleukin(IL)-4, IL-5, and IL-13, leading to allergic inflammation [8].
1.2 Pathogenesis of allergic asthma - lessons from
animal models
The clinical symptoms of allergic asthma are thoroughly investigated in patients, however,
fundamental questions, e.g. about the disease onset and the role of cells and mediators
involved, are mainly addressed in rodent models. These investigations broadened the
current knowledge about the patho-mechanisms that result in allergic asthma.
1.2.1 Sensitisation
Dendritic cells (DCs) are understood to be key players in immune responses as allergic
asthma, both in sensitisation as well as in maintenance of the disease [9]. As a prerequisite,
DCs need to be located at the site of the first contact to the allergen, i.e. in the bronchial
mucosa [10]. At this site, the allergen is incorporated, and afterwards processed by DCs
for initiating the sensitisation cascade.
After migration to the draining lymph nodes, the peptides of allergens are presented via
DC major histocompatibility complex (MHC) II to allergen specific T- and B-lymphocytes.
At this point, the DC importantly influences the immune response by the second signal
provided to the lymphocytes. Lung DCs seem to favour a Th2 response supposably by
delivering CD80/CD86-signals [11, 12], however, a simultaneous secretion of e.g. IL-12p70
by DCs will favour a Th1-response. This secretion of IL-12p70 by DCs can be induced
e.g. by toll-like receptor ligands [13].
After activation and proliferation, the allergen-specific lymphocytes invade the lung.
Allergic responses of the immune system are related to T helper cells type 2 (Th2)-
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lymphocytes. These cells can be found in elevated numbers in the airways and lung
tissue [14] and play a fundamental role in allergic asthma as underlined by depletion
experiments [15]. Activated Th2-lymphocytes secrete cytokines as IL-4, IL-5 and IL-13.
These mediators play a role in an altered neuronal control of glands in the submucosa
leading to a highly increased mucus production and thereby airway obstruction [16]. IL-13
is also thought to play a role in the development of airway hyper responsiveness [17].
Importantly, due to the release of IL-4 by Th2-cells, an isotype switch towards IgE is
induced in antibody-secreting B-lymphocytes (plasma cells). The allergen specific IgE
produced by these cells subsequently binds to Fcε-receptors on mast cells in the lung.
This process finalises the sensitisation and fulfils the prerequisite for allergic responses.
1.2.2 The effector phase of allergic asthma
In sensitised individuals, cross-linking of receptor-bound IgE after recontact to the allergen
causes activation and degranulation of mast cells very rapidly. Mediators released, e.g.
histamine and heparin, are responsible for clinical signs such as oedema of the bronchial
mucosa and constriction of the airway musculature. Moreover, leukotrienes lead to an
increased mucus production, smooth muscle contraction and invasion of inflammatory
cells into the lung [18].
Furthermore, mast cells secrete a variety of cytokines:
IL-5 and granulocytes and macrophages colony-stimulating factor (GM-CSF) influence
eosinophils, both during maturation in bone marrow and activation [19]. The role of IL-5
is controversially discussed: At least in mice, IL-5 plays a central role in asthma [20]. In
patients, therapies directed against IL-5 in fact reduced allergic inflammation, however,
airway hyper responsiveness was only moderately ameliorated [21, 22].
Other mast-cell released cytokines, e.g. IL-4 and IL-13, amplify the Th2-reaction and the
expression of cell adhesion molecules (VCAM-1) [23], thereby promoting the migration of
leukocytes into the lung tissue.
Three to six hours after re-contact with the allergen and lasting up to several days
without treatment, narrowing and hyper reactivity of the airways, eosinophilia of blood,
and profound eosinophilic inflammatory infiltrates in the lung tissue occur. This makes
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eosinophils to a main effector cell in allergic asthma. Eosinophils are attracted to the
lung due to chemokines as e.g. eotaxins [24]. They show proinflammatory effects through
a multitude of pre-synthesised mediators such as major basic protein (MBP), eosinophilic
cationic protein (ECP) and eosinophilic peroxidase (EPX). These mediators trigger the
release of histamine by mast cells, and moreover, they are toxic for parasites as well as
mammalian cells. Eosinophilic degranulation therefore causes severe tissue damage [25].
Additionally, eosinophil-mediators contribute to the constriction of the airways [16].
In summary, DCs play an important role in initiation and maintenance of the allergic
response, while eosinophils and Th2-lymphocytes are main effector cells of allergic asthma.
1.2.3 Chronic allergic asthma
In addition to the patho-mechanisms for acute-phase allergic asthma, the chronic phase
of allergic asthma is characterised by structural changes of the airway architecture, the so
called airway remodelling. Moreover, several cells and mediators emerge or change their
pattern of contribution to pathology.
These observations were made in chronic asthma models. Basically, these models use
ovalbumin for intraperitoneal or subcutaneous sensitisation with or without adjuvant as
for example alum to induce allergen-specific Th2-driven immune responses, followed by a
period of up to six months of either intranasal [26] or aerosolised [27, 28] allergen challenge
to provoke experimental asthma. But also transgenic mouse models exist: The induction
of Th2-responses and OVA-specific T cells is circumvented in mice overexpressing the
Th2-responses related transcription factor GATA3 in addition to T cells carrying an
OVA-specific receptor [29].
Remodelling
As an important characteristic of chronic asthma, the so called airway remodelling can be
reflected in animal models. Airway remodelling includes features as goblet-cell hyperplasia
[30, 31, 32], epithelial shedding, mucus hypersecretion [33], subepithelial fibrosis [34],
changes in the extracellular matrix, e.g. deposition of collagen and fibronectin, smooth
muscle hypertrophy [32], but also remodelling of large pulmonary vessels [35]. Due to
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anatomical differences to humans, remodelling is in mice more prominent in the main
bronchus [32, 26, 36]. These structural changes even persist after cessation of allergen
challenges, uncoupled from inflammation [36, 34, 32]. Additionally, mucins [31] and mucin
genes, e.g. Muc5a [37], are found, contributing to airway obstruction.
The mechanisms inducing all this structural alterations are not clearly understood yet,
although there are hints that several mediators contribute to these changes. Direct and
indirect contribution of IL-13, IL-10 and especially transforming growth factor (TGF)-β to
remodelling processes could be demonstrated [38, 32, 39, 37, 40, 41]. During chronification,
elevated TGF-β levels can be measured in bronchoalveolar lavage (BALF) [42]. Under
healthy conditions as well as in low-dose allergen models, epithelial cells are the main
source for TGF-β [43], but in allergic asthma invading eosinophils become more important.
TGF-β mediates pro-fibrotic [44] as well as anti-inflammatory effects, while on the one
hand inducing proliferation of fibroblasts and myofibroblasts and synthesis of extracellular
matrix proteins [45] and on the other hand suppressing lymphocytes [46].
Additionally, a class of endopeptidases, i.e. matrix metalloproteinases (MMPs) and
their inhibitors named tissue inhibitors of matrix metalloproteinases (TIMP), plays an
important role in the equilibrium of degradation and deposition of a variety of extracellular
matrix components, e.g. collagens and gelatines. A perturbation of the MMP/TIMP ratio
is believed to be responsible for a dysfunction of this equilibrium and thereby promotion
of remodelling [47, 48].
Cells and mediators in chronic asthma
The known main effector cells of acute-phase allergic responses also contribute to the
chronic phase, as CD4+ lymphocytes [49], eosinophils and mast cells.
Increasing numbers of mast cells can be found in chronically challenged mice [50, 31].
IL-5 and eotaxin play a pivotal role as anti-apoptotic and chemo-attractive mediators
in eosinophilic inflammation. The role of IL-5 in remodelling is not clarified yet: on the
one hand, studies demonstrate an induction of eosinophilia and remodelling [51] and
enhancement of airway reactivity related to IL-5. On the other hand subepithelial fibrosis
and epithelial hypertrophy seem to be unrelated to IL-5, thereby implicating a dissociation
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of remodelling and reduction of lung function [52].
Eotaxin expression shows differences when acute and chronic states were compared. Solely
eotaxin was not sufficient to attract eosinophils to the airways, but may modulate other
attractants [39].
Eosinophils are a main source of fibrogenic mediators as for example MMPs and TGF-β
and therefore contribute to remodelling [53, 54]. Eosinophil-deficient mice are protected
from both, an increase in collagen deposition as well as in smooth muscle mass in their
lungs [55].
Bleedings of chronically inflamed tissue can also promote fibrotic processes: Red blood cells
influence fibroblasts proliferation and apoptosis, and induce TGF-β and MMP secretion
[56, 57].
A generally inflammation-related cytokine, IL-6, can be found in chronic asthmatic states,
where it amplifies subepithelial fibrosis, but plays on the other hand a dual role by its
capacity to down-regulate chronic inflammation [58].
Airway hyper responsiveness (AHR)
Importantly, physiological parameters of chronic asthma can be induced and determined in
mice, which reflect an airway hyper responsiveness (AHR) to unspecific stimuli [26, 31, 59].
Fibrotic processes, e.g. observed during remodelling, are supposed to contribute to reduced
lung function [44]. Interestingly, during the chronic phase elevated levels of a classically
Th1-related cytokine, i.e. IFN-γ, can be measured [32], which may contribute to chronic
AHR [43]. For the occurrence of AHR in animal models maintained allergen challenges
seem to be necessary.
Studies showed an (alleviated) perpetuated airway inflammation, while AHR was absent
after cessation of challenges [27, 32]. Although AHR was also absent in animals chronically
challenged with low-level allergen doses, it could rapidly be induced, when a single moderate
dose was administered [28].
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1.3 Pharmacological intervention
For the treatment of asthma mainly symptom-alleviating pharmaceutics are applied. As
early as in 1881, phosphodiesterase inhibitors were discovered, and are nowadays one of
the most frequently applied asthma pharmaceutics [60]. Inhibition of phosphodiesterase
blocks the degradation of cyclic adenosine-monophosphate (cAMP), which results in
relaxation of airway smooth muscle. Via enhancement of intracellular cAMP-levels,
phosphodiesterase-inhibitors consequently act bronchodilatory [61]. Additionally, they an-
tagonise the bronchoconstrictor adenosine and bear anti-inflammatory potential, especially
synergistically with steroids [62].
The most important drugs in asthma therapy are β2-mimetics. Biologically, these
compounds are related to stress mediators, i.e. adrenalin. As in fight-and-flight reactions,
these substances show strong bronchodilatory effects by activating β2-adrenergic receptors
on airway muscle, thereby causing a relaxation and facilitation of deep breathing. β2-
mimetics are under suspicion to be responsible for an enhancement of airway hyper
reactivity, however, this finding seems to be of minor clinical relevance [63].
Leukotrien receptor antagonists show anti-inflammatory as well as a broncho-dilatory
effects. These are mediated via a replacement of the physiological cys-leukotrien (LT)
1-receptor ligands LTC4, LTE4 and LTD4. Especially LTD4 bears broncho-constrictive
actions. The anti-inflammatory effects are related to effects on granulocyte migration
[47, 64, 65, 66].
Corticosteroids, as dexamethasone, are prescribed frequently in severe allergic asthma.
This is due to their widespread beneficial effects on a variety of patho-mechanisms.
Dexamethasone is effective by inhibition of chemokine and Th2-cytokine transcription
and also inhibits phospholipase A, which is the catalyst for the first step in arachadionic
acid metabolism. As a result leukotriene and prostagladine synthesis is blocked, partly
explaining the anti-inflammatory effects of dexamethasone.
Additionally, the accumulation of leukocytes in the lung tissue can be suppressed by
administration of dexamethasone. [67, 68]. Also the clinical symptom of airway hyper
responsiveness can be attenuated, this effect is achieved by applying higher doses, though
[69].
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The interest in new and, more importantly, causative treatments is huge because of the
number of patients which are contraindicated or steroid non-responders. Especially the
class of steroids lost their acceptance because of side effects which for example occurred in
the treatment of skin diseases. Moreover, recent data implied that steroid treatment not
only augments inflammation and hyperreactivity, but also suppresses beneficial regulatory
immune responses as induction of regulatory T-cells [70].
The only causative treatment nowadays, the specific immune therapy (SIT), acts via this
induction of regulatory T-cells. Here, continued confrontation to the allergen is performed,
either by subcutaneous injections or as allergen extracts or tablets sublingually (sublingual
immune therapy, SLIT). The specific immune therapy modulates the immune response:
The allergen is incorporated by dendritic cells, which migrate to the draining lymph node.
Here, epitopes are presented to allergen-specific lymphocytes, and a regulatory T-cell
response is induced, characterised by IL-10 and TGF-β [71, 72].
However, not every allergy can be cured safely using SIT by now, although currently
the missing allergens are intensively investigated. Moreover, polysensitisations might
recommend a more general immuno-modulation. Importantly, such general immuno-
modulators, as for example toll-like receptor agonists, could also be effective drugs for
asthma and allergy prevention.
1.4 Agonisation of toll-like receptors as an innovative
pharmacological approach
Since a human homologue to drosophila toll-receptor had been firstly described [73],
several members of the TLR-family has been discovered. Toll-like receptors play an
important role in innate and adaptive immunity and in balancing immune responses with
tolerance. Different pathogens are recognised by specific patterns (pathogen-associated
molecular patterns, PAMPs), e.g. the TLR-5 ligand flagellin [74], lipopolysaccharide
(LPS) of gram-negative bacteria detected by TLR-4 [75], or CpG-unmethylated DNA
oligodesoxynucleotides binding to TLR-9 [76].
Immunostimulatory oligonucleotides as TLR9-ligating CpGs are promising innovative
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approaches in the therapy of asthma. They showed strong immunomodulatory capacity
in mice and are currently investigated in humans [77, 78]. But also TLR2 is related
to protection against allergies and allergic asthma by sensing PAMPs as mycobacterial
lipoproteins and lipopeptides. Interaction of host cells, preferentially antigen presenting
cells like dendritic cells (DC), with these ligands basically bears the potential to modulate
immune responses.
1.4.1 TLR2 in prevention of allergic asthma
Formulation of the hygiene hypothesis pointed out an inverse association of microbial load
and Th2 disorders [79, 6]. Additionally, genetic variations in TLR2, but not in TLR4,
which senses endotoxins [80], seem to be responsible for an observed protection of farmers’
children from allergy and asthma [4]. It might be of special importance to start these
protective actions already during pregnancy, when prenatal exposure to farm stables
upregulates TLR expression of neonatal cells [81]. Moreover, smoking during pregnancy
attenuates TLR-mediated immune responses, possibly increasing the risk for the offspring
to develop allergies and asthma [82].
1.4.2 Cellular TLR2 expression
TLR2 is expressed on a variety of cells, both structural as well as immune cells, in humans
and rodents as there are neutrophils [83], small airway epithelial cells as well as airway
smooth muscle cells [84, 85], tracheal muscle layer [86], monocytes [87], macrophages
[88], murine bone-marrow derived mast cells [89], and B cells [90, 91]. Its expression is
inducible by TNF-α and IFN-γ. Very importantly, TLR2 is also expressed on DCs, which
are due to their importance in immunity thought to be good target cells for modulating
immune responses [13, 92, 93].
TLR2 in general senses lipopeptides and lipoproteins, whereby different heterodimers
recognise different structures: diacylated lipopeptides, e.g. macrophage-activating lipopep-
tide, 2kD (MALP-2) [94], require TLR2/6 [83, 95], whereas triacylated lipopeptides, e.g.
Pam3CysSK4, are recognised by TLR2/1 [83] and lipoproteins by TLR2/4 [96]. Although
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effects of TLR2 agonisation dependent on the age of the experimental animal, such a
correlation is not observed in humans so far [88, 97].
1.4.3 Immune modulation in allergy and asthma mediated via TLR2
TLR2 agonisation bears the potential to both inhibit and promote development of immune
responses and is therefore manifold in its implementation. Different examples demonstrate
the various effects of TLR2 agonisation, either for shifting Th2 towards Th1 [98, 99],
aggravating Th2 [100] or induction of tolerance [101].
Its high immunomodulatory capacity as an adjuvant is further emphasised in experimental
vaccination against HIV and measles [102, 103, 104, 105]. This makes TLR2 agonisation
a promising approach for pharmaceutical intervention. TLR2 expression and function
is influenced by administration of steroids, e.g. dexamethasone [84]. Dexamethasone
suppresses receptor expression, however, receptor-upregulation by cytokines as IFN-γ and
TNF-α is amplified [84].
Mycoplasma infections prevent asthma, an effect which is partly dependent on the TLR2-
IFN-γ-pathway [106]. This finding led to the development of small Mycoplasma-derived
compounds for potential pharmacological intervention of allergic diseases.
1.4.4 BPPcysMPEG, a Mycoplasma fermentans-derived TLR2
agonist
A prerequisite for therapeutic purposes is the use of specific, pure and standardised
PAMP-receptor agonists. One of the few PAMP-agonists today available that fulfil
these criteria is the MALP-2 (Mycoplasma fermentans-related macrophage-activating
lipopeptide, 2kD) derived bisacyloxypropylcystein-conjugate (BPPcysMPEG, patent-
number WO 2004/009125 A2 Mühlradt/Morr).
BPPcysMPEG is a lipopeptide conjugate of the pathogen Mycoplasma fermentans, which
binds a double fatty acid substituted cystein via a carboxyl group to a polymeric conjugate
rest showing a high water solubility (fig. 1.1). Moreover, this conjugate rest is physiological
compatible and not immunogenic. A contamination of BPPcysMPEG with endotoxins
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is excluded to almost 100% due to its synthetic production, which means the risk for
sepsis is negligible. For its precursor molecule MALP-2 the immunomodulatory effect of a
treatment in combination with IFN-γ has previously been shown in an in vitro allergy
model [107]. In addition, efficacy of MALP-2 was proven in an ovalbumin mouse model
of acute-phase allergic asthma [98].
Figure 1.1: Structure of the toll-like receptor agonist BPPcysMPEG.
1.5 Improved mouse models of allergic asthma
1.5.1 Limitations of chronic models
Mouse models are useful tools to investigate the principal mechanisms involved in the
development of allergic asthma and provide useful hints for the understanding of the
disease and thereby possible intervention strategies. While studying acute-phase models,
the contribution of a variety of cells and mediators to allergic asthma could be described,
improving our current knowledge of the processes and mechanisms leading to this life
threatening disorder. But at the same time differences to the observed symptoms in
patients become more and more prominent, emphasising that allergic asthma is in fact a
chronic disease.
Chronic models are useful tools in asthma research; however, they show some limitations
when compared to human disease, which need to be improved.
One problem chronic models are facing is the resolution of airway eosinophilia [27, 43,
108], despite the fact that viability prolonging mediators for eosinophils are increasing
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throughout the duration of the protocols. For example, synthesis of neurotrophins, which
protect eosinophils of asthmatic patients from apoptosis [109], is upregulated by Th2-
cytokines, IL-1β and TNF-α [110]. Additionally, T-lymphocytes seem to play a regulatory
role in eosinophil viability. There is evidence that eosinophil apoptosis is mediated by Fas,
and Fas-deficiency on T cells is sufficient to cause a long term allergic inflammation [111].
Another obstacle is the induction of tolerance and immunosuppression [112]. Tolerance in
mice can be induced easily, which complicates to set up a model that replicates human
pathology. Although tolerance is a naturally occurring and beneficial process in allergic
diseases, the question remains what makes the immune system of allergic patients unable
to cope with the disease.
1.5.2 Getting closer to human pathology
Currently little is known about differences in the immunologic reaction when the provoca-
tion route is altered, although there are some evidences from animal models that the pace
of sensitisation is changed (topic vs. respiratory sensitisation in BN rats, reviewed in [113]).
By the use of an adjuvant a rapid and intense immune response is induced, shortening the
time of sensitisation and leading to severely inflamed tissues. Intraperitoneal sensitisations
with an adjuvant might on the one hand amplify and quicken the sensitisation, but remain
on the other hand incomparable to the human situation at all. In some models, the use of
an adjuvant can influence the investigation strongly [114]. Recently, first models were
described in which human relevant allergens could induce allergy symptoms by intranasal
administration [115].
Moreover, a milder course of the disease might reflect the human pathology more closely.
Besides the ability of developing characteristics of chronic asthma such as airway remod-
elling, an improved asthma model should provide similarity to the onset of the disease
in humans including relevant allergens. Several groups worked on new models which
use human relevant allergens either as recombinant proteins or extract preparations for
induction of allergic inflammation. For example, allergens from cockroach [116], As-
pergillus fumigatus [117] and house dust mite [30] in combination with adjuvant are
under investigation. In these new and optimised animal models very distinct questions
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can exclusively be investigated, for example from the field of desensitisation or specific
immunotherapy.
1.5.3 Grass pollen allergens
In addition to moulds and faeces enzymes of house dust mite, a main source for allergens are
grass pollen, e.g. of timothy grass Phleum pratense. Its major allergen 5 (Phl p5) is located
cytoplasmic and on the so-called pollen starch granules (PSG) [118], which represent
inspirable allergen carrying particles. Major allergen groups 1 and 5 are estimated to
represent the most important allergen groups, whereby ”almost 90% of grass pollen-allergic
patients are sensitized against group 5 grass pollen allergens” [119]. These allergens show
high immunogenicity in mice as well [120]. Meanwhile, recombinant Phl p5 as well as
highly standardised allergen extract preparations can be purchased from commercial
distributors, which allows the establishment of reliable and robust experimental protocols.
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1.6 Aim of this work
Subject of this work was the development and validation of an optimised murine model of
allergic asthma induced by Timothy grass pollen allergens, the characterisation of asthma
parameters in this model and assessment of the effects of a potential new pharmacological
intervention. The work includes the following steps:
1. Identification of susceptible mouse inbred lines
2. Establishment of a protocol to induce
• acute allergic asthma
• chronic allergic asthma
3. Assessment of effects of pharmaceutical interventions and immune modulation
• in a preventive regime
• in a therapeutic regime
with the standard therapeutic dexamethasone and the TLR2-agonist BPPcysMPEG
with/without the Th1-cytokine IFN-γ.
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2.1 Standard techniques
2.1.1 Housing of experimental animals
Mice were housed under a LD12-12 cycle, constant humidity and temperature in groups of
four to twelve mice per cage with ad libitum access to food and water. Microbiological and
virological health monitoring was performed routinely according to FELASA guidelines.
All animal experiments were performed with the permission of the local governmental
representation according to the animal welfare law (TierSchG) of Lower Saxony. A
minimum period of one week was allowed to acclimatise after transport from the breeders´
facility.
2.1.2 Intraperitoneal sensitisation towards recombinant Timothy
grass pollen allergen
Materials:
Recombinant Phl p5 Biomay, Vienna, Austria
NaCl solution (0.9%)
NaCl Merck, Darmstadt, Germany
Aqua bidest
ImjectAlum Pierce (via Perbio Science, Bonn, Germany)
Timothy grass pollen extract ALK Abello, Hørsholm, Denmark
Clean Bench Integra Bioscience, Chur, Switzerland
Three-way valve UNOPlast, (via VWR, Darmstadt, Germany)
Syringes (1 ml, 5ml) Braun, Melsungen, Germany
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Cannulas Braun, Melsungen, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
Inbred mice Charles River, Sulzfeld, Germany
Harlan Winkelmann, Borchen, Germany
Sensitisation was performed intraperitoneally with 5µg recombinant Timothy grass pollen
major allergen 5 (rPhl p5) and 1mg of Alum as adjuvant in 200µl sterile saline. The
allergen was absorbed to the adjuvant by forcing the solution through a three-way valve for
at least 5´. Sham sensitised animals received NaCl/Alum. Intraperitoneal sensitisations
were performed on day 1 and repeated on day 14 and 21.
2.1.3 Chronic respiratory sensitisation towards standardised Timothy
grass pollen allergen extract
Materials:
Timothy grass pollen extract ALK Abello, Hørsholm, Denmark
PBS Lonza Cambrex, Visp, Switzerland
Halothane (2-bromo-2-chloro-1,1,1-trifluoro-
ethane)
Sigma Aldrich, Taufkirchen, Germany
Vapour system Draeger, Hamburg, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
BALB/cAnCrl Charles River, Sulzfeld, Germany
Female BALB/c aged 6-8 weeks were obtained from Charles River. For intranasal
sensitisation, 50µl Timothy grass pollen extract containing a dose of 9µg major allergen
was administered under inhalative 2-bromo-3-chloro-trifluoran narcosis in a vapour system
twice a week on consecutive days. Negative controls received saline. Groups of animals
were assessed at different time points.
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2.1.4 Measurement of airway hyper responsiveness
Materials:
NaCl solution (0.9%)
NaCl Merck, Darmstadt, Germany
Aqua bidest
MCh Sigma Aldrich, Taufkirchen, Germany
Body for assessment of lung function Medical School Hannover, Hannover, Germany
Pressure Transducer Validyne Engineering Corp., Northridge, USA
Dry Cal DC-2 Bios International Corp., Butler, USA
Pneumotachographs Hugo Sachs Electronic, March, Germany
Amplifier Hugo Sachs Elektronik, March, Germany
Scantainer Scanbur LTD, Karlslunde, Denmark
Parimaster aerosol generator Pari (via Dr. Beckmann, Seefeld, Germany)
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
Latex "Dental Dam" collars Roeko, Langenau, Germany
Hem 3.4 software Notocord, Crossy-Sur-Seine, France
Airway hyper responsiveness to methacholine (MCh) was determined in non-anaesthetised
spontaneously breathing animals using head-out bodyplethysmography 24 hours after
the last allergen provocation. Baseline measurements were followed by provocation
with increasing doses of MCh diluted in 0.9% NaCl. MCh aerosols were generated
by a Pari Master aerosol generator. The respiratory signals were calculated from a
pneumotachograph linked to a DP45-14 differential pressure transducer and amplified
through a Carrier Frequency Bridge Amplifier. Flow dependent respiratory signals were
transduced into lung function parameters and continuously registered. For determination
of bronchoconstriction, the midexpiratory airflow (EF50), i.e. the expiratory airflow (ml/s)
at 50% tidal volume, was measured [121]. Respiratory signals were analysed using the
Hem 3.4 system (figs. 2.1, 2.2).
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Figure 2.1: Schematic drawing of the head-out body plethysmography device.
Figure 2.2: Photograph of mouse placed in head-out body plethysmography
device.
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2.1.5 Obtaining bronchoalveolar lavage fluid (BALF)
Materials:
PBS Lonza Cambrex, Visp, Switzerland
Narcoren Merial, Hallbergmoos, Germany
Pins and Scissors VWR, Darmstadt, Germany
Permanent venous catheter (Abbocath) Abbot GmbH & Co KG, Wiesbaden Germany
5ml PP-tube BD Falcon (via VWR, Darmstadt, Germany)
1ml syringes Braun, Melsungen, Germany
Cannulas Braun, Melsungen, Germany
Ice bath
Mice were sacrificed by injecting an overdose of Narcoren (1/5 diluted in PBS, 250µl per
mouse) and bronchoalveolar lavage (BAL) was performed.
The trachea was cannulated and the lung floated with 0.8ml ice-cold PBS twice, followed
by thoroughly winding up the syringe. BALF was pooled in 5ml polypropylene tubes
and immediately placed on ice until further processing.
2.1.6 Processing of BALF: Preparation of cytospins, differential
cytology, preservation of supernatant
Materials:
Giemsa staining solution Sigma Aldrich, Taufkirchen, Germany
May Grünwald staining solution Sigma Aldrich, Taufkirchen, Germany
PBS Lonza Cambrex, Visp, Switzerland
Cytofuge Shandon GmbH, Frankfurt a.M., Germany
Centrifuge Kendro, Langenselbold, Germany
ACT8 haematocytometer Beckmann Coulter, München, Germany
Neubauer chamber via VWR, Darmstadt, Germany
Microscope AxioVision2 plus Zeiss, Jena, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess. Oldendorf, Germany
Glass slides Menzel-Glaser, Braunschweig, Germany
Multitube storage box Greiner, Nürtingen, Germany
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BALF was centrifuged. Aliquots of the supernatant were stored at -70◦C for protein
quantification in ELISA. The cell pellet was resuspended in PBS and total cell counts were
determined with either Neubauer chamber or ACT haematocytometer. Approximately
2 × 105 cells were cytospun on glass slides using a cytofuge. To quantify and qualify
parameters of allergic inflammation cytospins were stained according to Pappenheim:
5´May-Grünwald, 2´ rinsed in PBS, 20´ in Giemsa (1/20 diluted in desalted water), rinsed
in tab water and air dried. Differential cell counts of 500 cells / slide were performed on a
microscope at 400-630x magnification due to morphological criteria (fig. 2.3). Eosinophils,
neutrophils, lymphocytes and macrophages were assessed.
Figure 2.3: Example of a Pappenheim stained cytospin of BALF cells (allergic
inflamed mouse). Four different cell types can be easily distinguished: macrophages
(blue cytoplasm and nucleus, huge), lymphocytes (blue nucleus, only little blue cytoplasm,
relatively small in size), neutrophils (polymorphic, segmented blue nucleus, clear to slightly
blue cytoplasm), eosinophils (polymorphic, segmented nucleus, granula in the cytoplasm are
stained red).
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2.1.7 Plasma sampling
Materials:
EDTA 0.5M Lonza Cambrex, Visp, Switzerland
Centrifuge Kendro, Langenselbold, Germany
1ml syringes Braun, Melsungen, Germany
Cannulas Braun, Melsungen, Germany
Eppendorff tubes (2ml) Eppendorff, Hamburg, Germany
Mice were bled via the vena cava. EDTA-plasma was prepared by centrifugation at
15,000 g for 10´ and preserved for determination of total IgG1 at -20◦C.
2.1.8 FACS measurements of spleenocytes and lung draining lymph
node cells
Materials:
RPMI+25mMHEPES Gibco Invitrogen, Karlsruhe, Germany
FACS buffer
5% FCS Sigma Aldrich, Taufkirchen, Germany
5mM EDTA Merck, Darmstadt, Germany
PBS Lonza Cambrex, Visp, Switzerland
FACS block buffer
Normal goat serum Dianova, Hamburg, Germany
1/25 in PBS Lonza Cambrex, Visp, Switzerland
Haemolysis buffer (pH7.3)
8.29 g NH4Cl Merck, Darmstadt, Germany
0.037 g Na2EDTA Merck, Darmstadt, Germany
0.839 g NaHCO3 Merck, Darmstadt, Germany
ad 1000ml Aqua bidest
Flowcheck Beckmann Coulter, München, Germany
Antibodies
CD45-FITC, foxp3-APC eBioscience Natutec, Frankfurt a.M., Germany
B220-FITC BD Bioscience, Heidelberg, Germany
CD11c-APC, CD4-PE BD Pharmingen, Heidelberg, Germany
CD45-FITC eBioscience Natutec, Frankfurt a.M., Germany
Rat IgG2a-PE, Rat IgG2a-FITC Becton Dickinson Pharmingen, Heidelberg, Germany
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Rat IgG2a-APC R&D bioscience, Wiesbaden-Nordenstadt, Germany
Armenian Hamster IgG-APC Becton Dickinson Pharmingen, Heidelberg, Germany
7AAD Beckman Coulter, München, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
Glass homogenator via VWR, Darmstadt, Germany
Centrifuge Kendro, Langenselbold, Germany
Cytomics FC500 flow cytometer Beckman Coulter, München, Germany
5ml PP-tube BD Falcon (via VWR, Darmstadt, Germany)
ice bath
Spleens were removed and rinsed with RPMI 1640+25mMHEPES. Erythrocytes were
lysed from the obtained cells suspension. All following steps were performed at 4◦C or on
ice, respectively. Approximately 105 spleenocytes as well as mediastinal lymph nodes cells
obtained in a 2ml glass homogenator of each individual were washed twice by adding 1ml
FACS buffer and subsequent centrifugation. Unspecific binding of antibodies was avoided
by incubation with FACS block buffer for 20´. Cells were stained with the following
antibodies and reagents: CD45-FITC/ 7AAD for determination of vital leukocytes in the
probe, B220-FITC and CD11c-APC to characterise professional antigen presenting cells
(e.g. B-lymphocytes and DCs), and CD4-PE followed by intracellular staining of foxp3-
APC for detection of regulatory T-lymphocytes, and appropriate isotype controls. After
one additional washing step, cells were analysed on Cytomics FC500. Before measurement
was started, the correct calibration of the FACS machine was controlled with FlowCheck
according to the distributor´s instructions.
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2.1.9 Histology and quantification of inflammatory and remodelling
processes in the lung
Materials:
OCT kryotec Sakura Finetek, Zoeterwoude, The Netherlands
PBS Lonza Cambrex, Visp, Switzerland
Aqua bidest
Liquid nitrogen Linde, München, Germany
Giemsa staining solution Sigma Aldrich, Taufkirchen, Germany
Azan novum according to Geidies
Nuclear fast red Merck, Darmstadt, Germany
China Blue Merck, Darmstadt, Germany
Acid Orange 52 Sigma Aldrich, Taufkirchen, Germany
Wolframato phosphoric acid Merck, Darmstadt, Germany
Aluminium sulphate solution Fluka (via Sigma Aldrich, Taufkirchen, Germany)
Acetic acid Roth, Karlsruhe, Germany
Isopropanol Roth, Karlsruhe, Germany
Methanol Merck, Darmstadt, Germany
Ethanol Merck, Darmstadt, Germany
Xylol Roth, Karlsruhe, Germany
Sircol Soluble Collagen Quantification Kit Biocolor Ltd, Newtownabbey, UK
Permanent venous catheter (Abbocath) Abbot GmbH & Co KG, Wiesbaden Germany
Eppendorff tubes (1.5ml) Eppendorff, Hamburg, Germany
Glass slides Menzel-Glaser, Braunschweig, Germany
Cover slides Menzel-Glaser, Braunschweig, Germany
1ml syringes Braun, Melsungen, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
Microscope AxioVision2 plus Zeiss, Jena, Germany
AxioVision Digital Camera and software Zeiss, Jena, Germany
Kryostat Leica, Bensheim, Germany
Right lung lobes were filled with a 1/4 dilution of OCT kryotek in PBS instilled through
the trachea. The lungs were removed and bedded in OCT to be immediately frozen in
liquid nitrogen. 5 or 14µm sagital sections displaying the main bronchus were prepared on
a Kryostat and either Giemsa or Azan novum stained. To detect red dyed eosinophils in
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tissue, Giemsa stained was performed by shortly dipping the 5µm thick sample into water,
followed by 1´May Grünwald , 1´ washing in PBS and 7´ in Giemsa 1/20 in distilled
water solution. Afterwards, the slides were differentiated in methanol and ethanol / acetic
acid, dehydrated 1´ in isopropanol and 3´xylol and covered with a cover slide. In Giemsa
stained sections, the field of view (FOV) in 400x magnification was adjusted to the
perivascular and peribronchial space. Eosinophils in this area were counted in three FOV
per animal (n=3 per group) in the proximal, middle and distal part of the main bronchus.
For visualising remodelling processes, 14µm sagital sections were Azan novum stained
according to Geidies. This method stains collagen and reticular connective tissue inten-
sively blue, mucous light blue, nuclei and musculature red and cell granula red to yellow.
The solutions were prepared as follows:
0.1 - 0.2 g nuclear fast red was solved in 100ml 5% aqueous aluminium sulphate solution
by short boiling. Afterwards the solution was simmered 5´ and filtrated after cooling
down. China Blue / Acid orange 52 mix: 0.5 g China Blue, 2 g Acid Orange 52 were
solved in 100ml Aqua bidest. Eight ml acetic acid were added, the solution shortly boiled
and filtrated after cooling.
After 30´ in Nucleus fast red solution slices were washed in Aqua bidest. Pickling was
performed for 10´ in 5% aqueous wolframato phosphoric acid, afterwards the slides
were rinsed in Aqua bidest. Before additional washing, slides were stained 2´ in China
blue /Acetic Orange 52 solution, dehydrated in isopropanol and xylol, and covered.
Photographs were taken at the distal part of the main bronchus with a digital camera
connected to a microscope.
Scoring of remodelling and inflammation in lung tissue
Evaluation of histo-morphologic alterations was performed blind to the experimental
groups. Lesions seen in the Giemsa-stained sections were scored for the overall severity
from 0 to 3 (0=no alterations, 1=mild, 2=moderate, 3= severe lesions). The amount of
inflammatory infiltrates was graded from 0 to 3 using the following criteria:
Very low amounts of inflammatory infiltrates near the primary bronchus were considered
as background lesions and graded as 0, as these infiltrations are most common in older
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mice. 1=moderate amounts of inflammatory infiltrates surrounding the primary bronchus.
2=moderate amounts of inflammatory infiltrates surrounding the primary bronchus
accompanied by moderate amounts of inflammatory infiltrates surrounding medium
sized bronchi and low amounts of inflammatory infiltrates surrounding small bronchi
and vasculature. 3=massive inflammatory infiltrates surrounding the main bronchus
accompanied by massive amounts of inflammatory infiltrates surrounding medium and
small bronchi and vasculature.
For the grading of the hyperplasia of the bronchial epithelium from 0 to 3, the following
criteria were applied: 0=normal bronchial epithelium. 1=mild mucosal hyperplasia
restricted to the primary bronchus. 2=moderate mucosal hyperplasia affecting the
primary bronchus as well as a few medium sized bronchi. 3= severe hyperplasia affecting
the main bronchus as well as the majority of medium sized bronchi.
Collagen quantification using Sircol Soluble Collagen Assay Kit
Preparation of lung samples started one day before measurement. Tissue was chopped in
small pieces, transferred to a weighed Eppendorff reaction tube and protease inhibitor
was added. Afterwards, the sample weight was measured. Samples were 1/10 diluted in
pepsin extraction solution and incubated overnight at 4◦C under agitation. The next day,
samples were centrifuged 60´ at 15,000 g and dye solution was added. Collagen standard
samples were prepared. Samples, standards and dye solution was incubated at room
temperature for half an hour and centrifuged at 21,500 g. Supernatant was discarded and
the pellet was resolved in alkali solution. Duplicates of samples, standards and blank were
transferred to a 96-well plate and photometrically measured at 540 nm. Collagen content
was calculated, expressed as promille wet weight. The kit contains the required solutions.
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2.1.10 Enzyme-linked immuno sorbent assay (ELISA)
Materials:
2 N H2SO4 Sigma Aldrich, Taufkirchen, Germany
TMB One (enzyme substrate) Biotrend, Cologne, Germany
Block Buffer
FCS Sigma Aldrich, Taufkirchen, Germany
BSA Sigma Aldrich, Taufkirchen, Germany
Succrose Merck, Darmstadt, Germany
PBS Lonza Cambrex, Visp, Switzerland
Sodium nitrite (NaN3) Sigma Aldrich, Taufkirchen, Germany
ELISA Wash buffer
PBS-Tween tablets Medicago, Uppsala, Sweden
Aqua bidest
MicroWell Plates Maxisorp NUNC GmbH & Co KG, Wiesbaden, Germany
Adhesive seals NUNC GmbH & Co KG, Wiesbaden, Germany
Combitips Eppendorff, Hamburg, Germany
ELISA reader Dynatech, Deisendorf, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess.Oldendorf, Germany
IgG1-Quantification Kit Bethyl Diagnostics Natutec, Frankfurt a.M., Germany
IL-5 and Eotaxin Duoset R&D bioscience, Wiesbaden-Nordenstadt, Germany
ELISA is a standard method to quantify proteins. Basically, a target specific capture
antibody is immobilised on a 96-well flat bottom plate and unspecific binding sites are
blocked by proteins as FCS or BSA. Afterwards, samples as well as standards are incubated,
followed by detection with a biotinylated detection antibody conjugated to horse-radish
peroxidase. Enzymatic reactions transform the substrate TMB, the reaction is stopped by
adding acid, the optical density is assessed photometrically and the protein concentration
of the sample is calculated. In this work, ELISA kits were used following the distributors´
instructions. Measured values of duplicates showing a coefficient of variation below 0.2
were believed to be valid.
For determination of IgG1 serum dilutions were incubated with capture antibody and
detected with a 1/75,000 dilution of the secondary detection antibody. Enzyme reaction
was stopped after 15´ by adding 2NH2SO4. Both antibodies were taken from IgG1
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quantification kit.
2.1.11 Bioplex-array for bead-based protein quantification
Materials:
10-plex bead-array Kit (IL-2,-4, -5, -6, -10,
-12p40, -12p70, TNF-α, IFN-γ, RANTES)
Biorad, München, Germany
Bioplex 200 system Biorad, München, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess. Oldendorf, Germany
For detection and quantification of ten cytokines and chemokines using fluorescence-
labelled micro beads, 10-plex bead-array was performed in BALF samples. Targets were
IL-2, -4, -5, -6, -10, -12p40, -12p70, TNF-α, IFN-γ and RANTES. A minimum of 100 beads
complexed with cytokines were assessed on Bioplex 200 System: the red laser identifies
the bead and the green laser reads the fluorescence intensity of the reporter molecule.
Afterwards, intensities are compared to a standard curve and proteins concentrations
in the sample are calculated. The 10-plex bead-array was performed according to the
manufacturer´s manual.
2.1.12 Statistical analysis
Materials:
Prism 4.03 Graph Pad Software Inc., San Diego, USA
To detect significant differences between groups, One-way ANOVA followed by Dunnet´s
multi comparison test and Student´s t-test was applied using the Graph Pad Prism 4
software. Results of p < 0.05 (∗), p < 0.01 (∗∗) and p < 0.001 (∗ ∗ ∗) were observed as
statistically different.
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2.2 Animal experiments
2.2.1 Development of a mouse model of acute-phase allergic
asthma induced by grass-pollen allergens of Timothy grass
Materials:
Aqua bidest
PBS Lonza Cambrex, Visp, Switzerland
Timothy grass pollen extract ALK Abello, Hørsholm, Denmark
Recombinant Phl p5 Biomay, Vienna, Austria
Timothy grass pollen Allergon, Ängelholm, Sweden
Ketanest Pfizer Pharma GmbH, Karlsruhe, Germany
Rompun Bayer Healthcare AG, Monheim, Germany
Centrifuge Kendro, Langenselbold, Germany
Clean Bench Integra Bioscience, Chur, Switzerland
Analysis balance Sartorius, Göttingen, Germany
Neubauer chamber via VWR, Darmstadt, Germany
Microsprayer Penn Centrury, Philadelphia, USA
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess. Oldendorf, Germany
Nylon mesh via VWR, Darmstadt, Germany
For additional materials see 2.1.2, 2.1.5, 2.1.6.
Determination of the mouse strain
Table 2.1: Overview of the different mouse strains tested for susceptibility for
sensitisation towards Timothy grass pollen allergens.
Breeder NEG n= POS n=
A/JOlaHsd Harlan, D 2 5
BALB/cAnCrl Charles River, D 2 5
CBA/J Charles River, D 2 5
C57/BL6 Charles River, D 2 5
To investigate whether inbred mice can be sensitised towards Timothy grass pollen
allergens, a comparative study was performed. Mice of different inbred strains (tab. 2.1),
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aged 6-8 weeks, were either sham-sensitised (n=2) or sensitised (n=5) on days 1, 14,
and 21. Intranasal rPhl p5 provocations were performed with 10µg protein in 50µl sterile
PBS on days 28 and 29. Monitoring of cellular inflammation in the lung was done by
bronchoalveolar lavage on day 30 and differential cytology.
Determination of the allergen source and the mode of administration
To investigate which allergen source and which route of administration for provocation
leads to allergic inflammation in the lung, a study was performed in which female
A/JOlaHsd mice aged 6-8 weeks were sensitised or sham-sensitised towards rPhl p5 as
mentioned above. Provocations were performed either with rPhl p5 i.n. or intratracheally
administered as an aerosol using microsprayer technique, freshly isolated pollen starch
granules of Timothy grass, or freshly prepared pollen extract from timothy grass pollen
both administered intranasally under ketamine / rompun anaesthesia.
Isolation of pollen starch granules and extract was performed as follows: PSG were isolated
under sterile conditions. Pollen grains were lysed by osmotic shock in Aqua bidest. Debris
was separated by centrifugation and supernatant (i.e. extract) was filtered through a 3µm
mesh to obtain PSG. Purity of PSG was controlled using a scanning electron microscope
(fig. 2.4). PSG were counted and adjusted to 8×108/ml in PBS to obtain an administered
dose of 4× 107 PSG in 50µl PBS per confrontation.
Figure 2.4: Electron scanning microscopic image of pollen starch granules ob-
tained from pollen grains. (Friendly provided by Andrea Westendorff, Fraunhofer
ITEM)
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Confirmation of the protocol to induce acute-phase allergic asthma
Female 8 week old BALB/cAnNCrl were obtained from Charles River and sensitised
towards rPhl p5/Alum (positive control, n=10). Sham sensitised animals received
NaCl/Alum (negative control, n= 10) (fig. 2.5). Sensitisation was repeated twice on days
14 and 21. To evoke allergic inflammation in the lung, mice were provoked intranasally
on two consecutive days with standardised P. pratense extract containing 9µg of major
allergen on day 27 and 28. On day 29, airway hyper responsiveness was measured in head-
out bodyplethysmography. Forty-eight hours after the last allergen challenge, mice were
sacrificed and bronchoalveolar lavage (BAL) and differential cell counts were performed.
BAL fluid was preserved for detection of cytokines using ELISA technique.
Figure 2.5: Protocol of acute-phase P. pratense induced allergic asthma.
BALB/c were sensitised to rPhl p5 or NaCl/Alum as control. Allergic inflammation in the
lungs was induced via i.n. challenges with P. pratense extract. Airway hyper reactivity
(AHR) to methacholine was measured using head-out bodyplethysmography. BAL was
performed 48 h after the last allergen challenge.
2.2.2 Intervention of acute-phase allergic asthma by a TLR2-agonist
Materials:
PBS Lonza Cambrex, Visp, Switzerland
BPPcysMPEG, TLR-agonist friendly provided by CA Guzman, Helmholtz Centre
for Infection Research, Braunschweig, Germany
Murine IFN-γ Strathmann Biotech, Hamburg, Germany
Dexamethasone Ratiopharm, Ulm, Germany
Halothane (2-bromo-2-chloro-1,1,1-trifluoro-
ethane)
Sigma Aldrich, Taufkirchen, Germany
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Ketanest Pfizer Pharma GmbH, Karlsruhe, Germany
Rompun Bayer Healthcare AG, Monheim, Germany
Vapour system Draeger, Hamburg, Germany
1ml syringes Braun, Melsungen, Germany
Cannulas Braun, Melsungen, Germany
Pipette Labsystem, Vantaa, Finland
Pipette tips Biozym, Hess. Oldendorf, Germany
For additional materials see 2.1.2, 2.1.4, 2.1.5, 2.1.6.
Determination of TLR2-agonist BPPcysMPEG and IFN-γ treatment dose
To determine treatment doses of BPPcysMPEG and IFN-γ, dose finding studies were
performed. Four groups of mice (BALB/cAnCrl, n=5) were treated i.n. thrice with
a pause of one week with either 20 ng (≈ 6.67 × 1019 mol), 10 ng (≈ 3.33 × 1019 mol),
4 ng (≈ 1.67× 1019 mol) or 2 ng (≈ 6.67× 1018 mol) BPPcysMPEG, respectively. Their
condition and their body weight were monitored during the whole period. Twenty-four
hours after the last treatment, animals were sacrificed and BALF was obtained. Cytospin
preparations and differential cell counts were performed to investigate the inflammatory
capacity of the treatment, i.e. induction of neutrophilia.
Prevention of acute-phase allergic asthma
To investigate asthma preventive effects of BPPcysMPEG/IFN-γ treatment, groups of 4
week old female BALB/cAnNCrl (n= 8) were treated thrice before the first and additionally
before every recurrence of sensitisation leading to five times of treatment as follows: vehicle
control (negative treatment control) i.n., dexamethasone i.p. (positive treatment control,
0.5mg/kg body weight), 2 ngBPPcysMPEG i.n., 5×103U IFN-γ i.n., 2 ngBPPcysPEG/5×
103UIFN-γ i.n (fig. 2.6). All treatments were performed under ketamine / rompun
anaesthesia. Standard acute P. pratense model was performed as described earlier.
Read-out, i.e. measurement of airway hyper responsiveness to methacholine using head-
out bodyplethysmography and monitoring of cellular inflammation by performing a
bronchoalveolar lavage was done 24 h after the last allergen provocation.
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Figure 2.6: Preventive asthma treatment protocol in the acute P. pratense
model. Groups of n=8 BALB/c mice were treated with vehicle, dexamethasone, BPP-
cysMPEG, IFN-γ or BPPcysMPEG/IFN-γ, respectively, at indicated time points (red). All
animals were sensitised against rPhl p5.
Therapeutic treatment of established acute-phase allergic asthma
To investigate therapeutic effects of BPPcysMPEG/IFN-γ treatment, groups of 6-8 week
old female BALB/cAnNCrl (n=8) were sensitised towards rPhl p5 and treated in a
therapeutical setting as follows: vehicle control (negative treatment control) i.n., dexam-
ethasone i.p. (positive treatment control, 0.5mg/kg body weight), 2 ngBPPcysMPEG i.n.,
5 × 103UIFN-γ i.n., 2 ngBPPcysMPEG/5 × 103UIFN-γ i.n (fig. 2.7). All treatments
were performed under ketamine / rompun anaesthesia. Measurement of airway hyper
responsiveness to methacholine using head-out bodyplethysmography and assessment of
cellular inflammation by performing a bronchoalveolar lavage was done 24 h after the last
allergen provocation. Supernatant of BALF was preserved for quantification of IL-5.
Figure 2.7: Therapeutic asthma treatment protocol in the acute P. pratense
model.
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Preventive treatment of sensitised animals before allergen provocation
This study was performed analogue to that of Weigt et al. [98]. To investigate whether
allergic inflammation could be prevented by BPPcysMPEG/IFN-γ treatment, groups of 8
week old female BALB/cAnNCrl (n= 12) were treated before the first allergen provocation
as follows: vehicle control (negative treatment control) i.n., dexamethasone i.p. (positive
treatment control, 0.5mg/kg body weight), 2 ngBPPcysMPEG i.n., 5× 103UIFN-γ i.n.,
2 ngBPPcysMPEG/5 × 103UIFN-γ i.n. (fig. 2.8). Treatment was performed under
ketamine / rompun anaesthesia. Standard acute P. pratense model was performed as
described earlier. Read-out, i.e. measurement of airway hyperresponsiveness to metha-
choline using head-out bodyplethysmography and monitoring of cellular inflammation by
performing a bronchoalveolar lavage, was done 24 h after the last allergen provocation.
Figure 2.8: Preventive treatment protocol of allergic asthma in the acute P.
pratense model. Groups of 12 mice were sensitised against rPhl p5 and treated with
vehicle, dexamethasone, BPPcysMPEG, IFN-γ or BPPcysMPEG/IFN-γ, respectively, at
day 27 (red).
2.2.3 Therapeutic intervention in sub-chronic asthma
The study included the groups summarised in tab. 2.2. Sampling was performed at three
different time points (i.e., after 2, 10 and 22 allergen provocations). For the two earlier
time points the group size was n=8 each, for the latest time point 14 animals per group
were assessed.
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Table 2.2: Scheme on the different study groups.
i.p. sensitisation allergen provocation Treatment
NEG NaCl/Alum NaCl NaCl i.p.
POS rPhl p5/Alum P. pratense extract NaCl i.p. & i.n.
DEX rPhl p5/Alum P. pratense extract Dexamethasone i.p. & i.n.
B 2/I rPhl p5/Alum P. pratense extract BPPcysMPEG/IFN-γ i.n.
To sensitise mice intraperitoneally towards grass pollen allergen, BALB/cAnNCrl aged 8
weeks were treated according to the above mentioned standard protocol (2.9). From day
28 on, allergen provocations were performed in all groups twice a week on two consecutive
days using P. pratense extract (9µg major allergen per mouse/treatment) under halothane
narcosis. Negative control group received saline. Fifteen and two hours before every
provocation, a group of 8-14 mice was treated with 0.5mg/kg dexamethasone i.p., while
positive and negative control group received saline injections. B 2/I-group received 2 ng
BPPcysMPEG/5 × 103 IFN-γ one day after the second allergen provocation per week.
Read-out parameters, i.e. measurement of AHR and sampling (preservation of BALF
and serum and fixation of lung in formalin solution, Sigma Aldrich, Taufkirchen) were
assessed after 2, 10 and 22 allergen provocations.
Figure 2.9: Protocol of sub-chronic P. pratense induced allergic asthma.
BALB/c were i.p.-sensitised to rPhl p5 or NaCl/Alum as control. Dexamethasone treatment
was performed 15 and 2 h before every allergen provocation. Airway hyperreactivity to
methacholine was measured using head-out bodyplethysmography. BAL was performed 24 h
after the last allergen challenge.
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2.2.4 Chronic intranasal sensitisation to Timothy grass extract and
modulation with a toll-like receptor agonist and/or IFN-γ
Materials:
For materials see 2.1.3, 2.1.4, 2.1.9, 2.1.10, 2.1.11, 2.2.2
Preventive intervention of chronic respiratory sensitisation towards Timothy grass
pollen extract
Female BALB/c aged 6-8 weeks were obtained from Charles River and applied for the
standard model of chronic respiratory sensitisation (fig. 2.10, section 2.1.3). Unless
indicated, groups of n= 10 animals per treatment group were assessed after 30 intranasal
provocations. To monitor the course of sensitisation and inflammatory responses, satellite
groups of n=10 were sacrificed after 10 and 22 provocations. Read-out parameters were
measured, i.e. in BALF (cellular composition and cytokines/chemokines in supernatant
using ELISA and Bioplex array), lung tissue (histology and quantification of inflammatory
and remodelling processes), mediastinal lymph node and in spleen cells (FACS analysis).
Figure 2.10: Preventive treatment protocol of in the model of chronic respira-
tory sensitisation.
Treatment
Treatments were performed during the phase of respiratory sensitisation, 8 h after the
second weekly provocation intranasally starting after the tenth provocation. Sham-
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treatment with saline was performed in negative and positive controls, while one group
received 2 ngBBPcysMPEG/5× 103UIFN-γ (B2/I), 4 ngBBPcysMPEG/5× 103UIFN-
γ (B4/I), 5 × 103UIFN-γ (I), or 4 ngBPPcysMPEG(B4) in 50µl saline, respectively.
Positive treatment control received 0.5mg/kg BW dexamethasone in 200µl sterile saline
intraperitoneally 18 and 2 h before each provocation.
3 Results
3.1 Development of an acute-phase asthma model
induced by Timothy grass pollen allergens
3.1.1 Acute allergic inflammatory responses can be induced in
different inbred mice strains
When applied to the standard intraperitoneal sensitisation protocol (fig. 2.5) and chal-
lenged with the recombinant major allergen 5 of Timothy grass (rPhl p5), the four tested
inbred mice strains A/J, BALB/c, C57/BL6 and CBA/J showed elevated total cell counts,
as well as eosinophil and lymphocyte numbers in BALF. At the same time, only weak
neutrophilia was observed (fig. 3.1). Differential cytology on BALF cells therefore clearly
demonstrates an allergic inflammation.
Two things were taken under advisement to conclude which inbred strain would be most
suitable. Looking at the cellular composition of BALF, not only high eosinophil counts,
but also elevated lymphocytes and an only light neutrophilia were believed to reflect
human asthma closer. When the ratio of the different cell types towards each other was
taken into consideration, susceptibility to the onset of allergic inflammation among the
different strains was most prominent in A/J mice, followed by BALB/c, C57/BL6 and
CBA/J. Additionally, for the development of a chronic model A/J and BALB/c seem to
be the most suitable due to their ability of developing perpetual cellular inflammation
[122]. Because the aim of this work was to establish both, an acute-phase and a chronic
model of allergic inflammation, in the following experiments A/J and BALB/c mice were
set into the focus of investigation.
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Figure 3.1: Differential cell counts in BALF in different inbred mouse strains.
Mean and SEM are shown. Four different mouse strains were either sham-sensitised
(n= 2) or sensitised (n= 5) towards rPhl p5/Alum and provocated with recombinant protein
intranasally. Due to the small group sizes, no statistical significances could be detected.
3.1.2 Acute allergic inflammatory responses develop in sensitised
mice after provocation with natural occurring allergen sources
To achieve a controlled sensitisation towards Timothy grass allergens, A/J mice were
immunised by three rPhl p5/Alum injections within 21 days. Provocations with rPhl p5
were performed either intranasally or intratracheally as an aerosol. To resemble human
pathology more closely regarding the induction of effector mechanisms of allergic asthma,
sensitised mice were provocated with naturally occurring allergen sources, i.e. pollen
starch granules and whole pollen grain extract containing proteins and lipids.
PSGs are believed to be the allergen carrying particle actually responsible for induction
of allergic asthma in patients, because they are small enough to be inhaled into the deep
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Figure 3.2: Differential cell counts in BALF after challenge with different aller-
gen sources. Mean and SEM are shown. Two different application modi, i.e. intranasal
and intratracheal administered aerosol, as well as three different Timothy grass pollen
allergen sources, i.e. recombinant allergen rPhl p5, pollen starch granules (PSG) as well as
pollen extract, were tested for provocation of acute allergic inflammation in A/J mice (NEG
n= 5, POS n=5).
airways. Also in experimental asthma, an intranasal PSG-provocation in sensitised mice
increases eosinophil counts. However, soluble mediators of PSG preparations, supposedly
endotoxins, seem to cause neutrophilia in sensitised, but also in sham-sensitised control
animals. This excludes the use of PSGs in experimental models.
A clear induction of eosinophils in sensitised mice provocated with either the recombinant
allergen or pollen extract could be detected (fig. 3.2). Interestingly, although intranasally
administered recombinant protein was the most efficient to induce allergic inflammation,
the BALF clearly showed elevated neutrophil counts, either when i.n. or i.t. administered.
However, the induction of eosinophils in intratracheally aerosol challenged mice circumvents
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the nose, and therefore excludes a limitation of the allergic processes to the upper parts
of the airways.
An allergen confrontation does normally not happen with a single protein, but with a
cocktail of substances. To improve the protocol e.g. towards standard ovalbumin-induced
models with respect to resembling human pathogenesis, extract challenges seemed to be
more advantageous. Moreover, in the following studies self-prepared extract could be
substituted by highly standardised commercially distributed extract used for provocation
diagnosis in humans.
However, measurement of airway hyper responsiveness proved to be unpractical due to
abnormal reaction of A/J mice towards the methacholine aerosol. To enable assessment
of lung function, BALB/c mice were chosen for all following experiments.
3.1.3 Acute-phase allergic asthma reflecting inflammatory as well as
physiological parameters can be induced in mice
In mice sensitised to rPhl p5 and challenged with standardised extract intranasally (see 2.5),
allergic inflammation as well as airway hyper responsiveness could be induced. Absolute
cell counts in BAL fluid revealed significant higher numbers in sensitised BALB/c mice
compared to sham sensitised animals (fig. 3.3). The counts of main effector cells in
allergic response, i.e. eosinophils, were significantly elevated in sensitised animals, as were
lymphocytes and to a moderate extent neutrophils. Measurement of IL-5 in BAL fluid
showed significantly higher levels in sensitised mice compared to sham-sensitised mice (fig.
3.3).
Determination of airway hyper responsiveness was performed using head-out bodyplethys-
mography. The effective dose of methacholine (MCh) which caused a 50% decline in
midexpiratory flow (EF50) was calculated (ED50EF50) after sigmoid curve fitting of dose
response curves for each individual. The positive control group reacted with a decline
in airflow at lower doses of MCh compared to negative control, indicating a clear hyper
reactivity of their lungs (fig. 3.4).
This new model of acute-phase allergic asthma induced by Timothy grass pollen allergens
reflects important characteristics of human asthma. Also the allergen source used is of
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Figure 3.3: Differential cell counts and IL-5 in BALF in the acute model. Mean
and SEM are shown. BALB/c were sensitised to rPhl p5 and challenged intranasally with
standardised Timothy grass pollen allergen extract (n=10 per group) according to the
standard protocol.
important clinical relevance. Moreover, biological variances in allergenicity of the allergen
preparations used are minimised as far as possible. Therefore, the reliable model can now
be applied for efficacy tests of new pharmaceuticals, as e.g. TLR-ligands.
Figure 3.4: Effective dose of methacholine that decreases midexpiratory flow to
50% (determination of airway hyper responsiveness) in the acute model. Mean
and SEM are shown. Positive control reacted at significant lower doses of methacholine
with a decline of midexpiratory flow, clearly indicating an existing hyper responsiveness
compared to negative control (n=10 per group).
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3.2 Development of a chronic model of allergic
inflammation induced by Timothy grass pollen
allergens
3.2.1 Intraperitoneal sensitisation followed by chronic allergen
provocations causes transient severe allergic inflammation
Intraperitoneal sensitisation towards rPhl p5 followed by a prolonged period of repeated
intranasal extract challenges (see 2.9) rapidly results in severe allergic inflammation. After
eleven weeks of challenge (22 provocations) the allergic inflammation remains statistically
significant elevated, although it is alleviated in BALF (fig. 3.5). Due to this reduction
of cellular inflammation in positive controls at the last time point assessed, therapeutic
effects of dexamethasone could not be detected after 22 provocations, although eosinophil
counts in dexamethasone-treated animals remained stable over time.
Additionally, measurement of airway hyper responsiveness resulted in a surprising decline
in ED50EF50 in sham-sensitised and -challenged controls (fig. 3.6). This might be due to
chronic administrations of liquid into the lung, or, possibly more likely, a phenomenon of
the ongoing aging of the animals. However, measurement of airway hyper responsiveness
revealed no reliable differences between the groups at any time-point and could therefore
not be established as a read-out parameter for this mouse model.
Remodelling processes are self-evidently occurring at the time point after 22 provocations
(fig. 3.7), underlining that this important feature of the chronic phase of allergic asthma
could be reflected.
However, the fact that a clear abrogation of eosinophilic inflammation by dexamethasone
treatment could not be demonstrated at the latest time point, limits this model to
reflecting a sub-chronic phase, i.e. ten provocations, in pharmacological intervention. At
this time point, clearly elevated eosinophil and lymphocyte counts could be measured.
Further on, dexamethasone showed the expected beneficial effects.
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Figure 3.5: Differential cell counts in BAL fluid in the sub-chronic model. Time
course over the duration of the study. Mean and SEM are displayed. Negative control
group (NEG, blue line), i.p.-sensitised positive control group (POS, red line), i.p.-sensitised
dexamethasone treated group (DEX, green line). Every group was assessed after 2 (n=8),
10 (n=8) and 22 (n=14) provocations. Some data on this graph is also shown in figs. 3.15,
3.17.
Figure 3.6: ED50EF50 (MCh) of i.p.-sensitised negative controls during contin-
uation of the experiment. Mean/SEM of the effective dose of methacholine in µg, which
causes a decrease of the midexpiratory airflow to 50% are depicted.
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Figure 3.7: Histology on lung sections (Masson Goldner) of the chronic model
using i.p.-sensitisations. Every group was assessed after 22 provocations. Masson
Goldner stained sections on formalin-fixed paraffin-embedded lungs were provided by the
Department of Pathology, Dr. Susanne Rittinghausen, Fraunhofer ITEM. Photographs
were taken at 400x magnification at the distal part of the main bronchus. The results
are as follows: Nuclei are stained brown-black, cytoplasm red, erythrocytes orange-yellow,
connective tissue and sour mucus green.
3.2.2 Respiratory sensitisation to Timothy grass pollen allergens
results in perpetuated allergic inflammation
When mice underwent the protocol of respiratory sensitisation (see 2.10), the results were
as follows:
Throughout the protocol a prominent increasing allergic inflammation was induced,
displayed by exaggerated total cell counts, eosinophil and lymphocyte numbers, and only
moderate neutrophilia (fig. 3.8). This inflammation can be reduced to normal levels by
dexamethasone treatment, as observed in patients. As in intraperitoneally sensitised mice,
measurement of airway hyper responsiveness failed to result in a significant difference
between intranasally sensitised and sham-sensitised animals (fig.3.9). However, the model
of chronic respiratory sensitisation resembles human allergic airway inflammation closely
regarding the allergen used, the route of sensitisation and the route of recurrent allergen
confrontations, and in responses to standard treatments. Therefore, and because of the
ability to reflect chronic eosinophilia, it is an important complement to common chronic
asthma models.
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Figure 3.8: Differential cell counts in BALF in the model of chronic respiratory
sensitisation. Time course over the duration of the study. Mean and SEM are displayed.
Negative control group (blue line), sensitised positive control group (red line), sensitised
dexamethasone treated group (green line). Every group was assessed after 10, 22 and 30
provocations. Some data on this graph is also shown in fig. 3.19.
Figure 3.9: ED50EF50 methacholine in the model of chronic respiratory sensiti-
sation. After 30 extract provocations, no difference between sham-sensitised and sensitised
animals (n=12, each) could be observed.
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3.3 TLR2-agonists in intervention of allergic asthma
3.3.1 Titration of BPPcysMPEG and IFN-γ dose
Before BPPcysMPEG and IFN-γ could be administered for treatment of allergic asthma,
dose finding studies were performed. First, different doses of IFN-γ were titrated against
a constant dose of BPPcysMPEG, adapted from studies using the precursor molecule
MALP-2 (fig.3.10). In a second step, the dose of BPPcysMPEG was titrated. Neither a
decline in body weight, nor an influence on their general condition was observed in any
treatment group. It has to be remarked that in the first set of dose finding-experiments, the
groups receiving 10 ng and 20 ng of BPPcysMPEG/IFN-γ showed side effects in behaviour
in terms of exaggerated locomotor and aggressive behaviour. When the experiment
was repeated, these side effects did not occur any longer; the causative relation of this
observation to the treatment could not be proven. However, the work was continued with
the two lower doses, keeping in mind that repeated administrations would be needed in
the sub-chronic and chronic model.
Tolerable doses, i.e. doses not resulting in an increase in total cell counts, mild neutrophilia
of the BAL fluid cells and no behavioural side effects, were used for further experiments.
Titration revealed a dose of 5× 103UIFN-γ and 2 ng or 4 ngBPPcysMPEG for further
studies.
3.3.2 Prevention of acute allergic asthma can be achieved by
TLR2-agonist/IFN-γ-treatment
Whether synthetically produced Mycoplasma-lipopeptide derived compounds as BPPcysM-
PEG can bear the same asthma preventive effects as observed for prior-to-sensitisation
Mycoplasma-infections, was investigated in a preventive protocol (see 2.6).
In this preventive protocol TLR2-agonisation started before sensitisation and contin-
ued throughout this phase. When allergic inflammation was provoked by intranasal
extract challenges, no significant effect on absolute cell counts was observed. Impor-
tantly, eosinophil counts in BAL fluid were significantly diminished in dexamethasone and
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Figure 3.10: BPPcysMPEG and IFN-γ dose titration. Neutrophil counts in BALF.
Mean and SEM are shown. Left: after treatment with 20 ngBPPcysMPEG and titrated doses
of IFN-γ. Right: after treatment with 5× 103U IFN-γ and titrated doses of BPPcysMPEG.
For further studies a dose of 5× 103U IFN-γ and 2 ng or 4 ngBPPcysMPEG was chosen.
BPPcysMPEG/IFN-γ treated mice. No treatment group showed increased neutrophil
counts in BAL fluid (fig. 3.11). This proves the concept of a possible TLR2-mediated
prevention of allergic inflammation and underlines the pharmacological potential of
BPPcysMPEG.
Measurement of airway hyperresponsiveness showed that significantly elevated doses of
methacholine were necessary to reduce midexpiratory flow to 50% in the dexamethasone
treated group. Although calculation of statistical power revealed that this measurement
actually requires larger group sizes, BPPcysMPEG/IFN-γ-treated animals showed a clear
tendency to improved lung function (p=0.08) (fig. 3.12).
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Figure 3.11: Differential cell counts in BALF in the preventive intervention
of acute-phase asthma. Mice were treated in a preventive treatment regime, i.e.
before and during the phase of sensitisation (n=8 per group). POS= sensitised vehi-
cle control, DEX=dexamethasone treated group, B 2=2ngBPPcysMPEG, I= IFN-γ,
B2/I=2ngBPPcysMPEG/IFN-γ.
Figure 3.12: Effective dose of methacholine that decreases midexpiratory flow
to 50% (airway hyperresponsiveness) in preventively intervened acute asthma.
Mice were treated before and during sensitisation (n=8). Mean and SEM are shown.
POS= sensitised vehicle control, DEX=dexamethasone, B 2=2ngBPPcysMPEG, I= IFN-
γ, B 2/I= 2 ngBPPcysMPEG/IFN-γ. A statistically significant improvement of lung function
was observed in dexamethasone-treatment group, however, B 2/I reached p=0.08.
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3.4 Intervention of acute-phase allergic asthma by a
TLR2-ligand
3.4.1 A single preventive administration of TLR2-agonist/IFN-γ
ameliorates lung function in sensitised mice
To test asthma preventive effects in already sensitised mice, treatment was performed
one day before allergic inflammation was induced in the lung by extract provocation (see
2.8). A single preventive treatment turned out to be not sufficient to influence the allergic
inflammation, however, it ameliorated lung function significantly. No treatment effect was
observed in any group when looking at total BAL fluid cell counts, eosinophil or neutrophil
numbers (fig. 3.13). Measurement of airway hyper responsiveness to methacholine revealed
a significantly improved lung function in BPPcysMPEG/IFN-γ-treated mice (fig. 3.14).
Figure 3.13: Differential cell counts in BALF in preventive intervention of acute
asthma in sensitised mice. Mice were treated one day before the first extract provo-
cation (d 27, n=12). POS= sensitised vehicle control, DEX=dexamethasone, B 2=2ng
BPPcysMPEG, I= IFN-γ, B 2/I= 2 ngBPPcysMPEG/5× 103U IFN-γ.
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Figure 3.14: Effective dose of methacholine that decreases midexpiratory flow to
50% (airway hyper responsiveness) in preventive intervention of acute asthma in
sensitised mice. Mice were treated at day 27, one day before the first extract provocation
(n=12 per group). POS= sensitised vehicle control, DEX=dexamethasone, B 2=2ng
BPPcysMPEG, I= IFN-γ, B 2/I= 2 ng BPPcysMPEG/IFN-γ. B 2/I-group showed improved
lung function compared to the vehicle treated positive control.
3.4.2 A single therapeutic administration of TLR2-agonist/IFN-γ
ameliorates allergic inflammation in sensitised mice
A single administration of the TLR2-agonist in combination with IFN-γ one day after the
last allergen challenge (see 2.7) showed a significant amelioration of cellular inflammation
(fig. 3.15).
Although absolute cell counts were not altered, eosinophil counts as well as neutrophils
were diminished comparable to dexamethasone treated controls. Therefore, a therapeutic
treatment with BPPcysMPEG and IFN-γ demonstrated to have strong beneficial influence
on allergic inflammation.
Augmentation of lymphocytes did not reach a statistical significance, as did measurement
of airway hyper responsiveness (fig. 3.16).
From the studies performed in sensitised mice it becomes obviously that the time point
of pharmacological intervention influences amelioration of disease-related symptoms
noticeably. While effects on lung function parameters seem to depend on an early start
of treatment in a preventive manner, inflammation-related symptoms can effectively be
alleviated after allergen confrontation.
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Figure 3.15: Differential cell counts and IL-5 in BALF in therapeutic interven-
tion of acute-phase asthma. Mice were treated at day 29, one day after the last provo-
cation, in a therapeutic protocol (n= 8 per group). NEG= sham-sensitised negative control,
POS=sensitised vehicle control, DEX=dexamethasone, B 2/I=2ngBPPcysMPEG/5×
103U IFN-γ.
Figure 3.16: Effective dose of methacholine that decreases midexpiratory flow to
50% (airway hyper responsiveness) in therapeutic intervention of acute asthma.
Mean and SEM are shown. Mice were treated at day 29, one day after the last provocation
(n=8 per group), in a therapeutic protocol. NEG=sham-sensitised negative control,
POS= sensitised vehicle control, DEX=dexamethasone, B 2/I= 2 ngBPPcysMPEG/IFN-γ.
No significant differences could be detected among the groups, indicating no improvement
of lung function compared to positive controls.
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3.5 Intervention of chronic allergic asthma by a
TLR2-ligand and IFN-γ
3.5.1 Sub-chronic allergic inflammation in intraperitoneal sensitised
mice is influenced by dexamethasone and therapeutic
TLR2-agonisation in combination with IFN-γ
To investigate the effects TLR-agonisation could have on the sub-chronic phase of allergic
asthma, the protocol was applied as shown in 2.9. Treatment was performed one day
after the second allergen provocation per week.
In a sub-chronic phase, i.e. after ten extract provocations, eosinophils as well as neutrophils
were significantly reduced in therapeutically BPPcysMPEG/IFN-γ treated mice compared
to untreated positive controls.
Dexamethasone showed a generally inflammation-dampening character: total cell counts
in BALF, eosinophils and lymphocytes were reduced. Neutrophils were not affected by
dexamethasone treatment (fig. 3.17).
For a chronic phase of allergic asthma and also due to the closer resemblance to hu-
man pathology, focus was set to the investigations in the model of chronic respiratory
sensitisation.
3.5.2 Prevention of chronic allergic asthma by dexamethasone, a
TLR2-agonist and IFN-γ in a model of respiratory sensitisation
To resemble human pathology more closely, the model of chronic respiratory sensitisation
towards grass pollen allergens was used. Intranasal treatment was performed 8 h after
the second extract confrontation (see 2.10). Dexamethasone-treatment was performed
intraperitoneally 18 h and 2 h before each provocation.
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Figure 3.17: Differential cell counts in BAL fluid in intraperitoneal sensitised
mice after 10 extract provocations (sub-chronic phase). Mean and SEM are dis-
played. Negative control group (NEG), i.p.-sensitised positive control group (POS), i.p.-
sensitised dexamethasone treated group (DEX), 2 ngBPPcysMPEG/IFN-γ treated group
(B 2/I). Every group consisted of (n=8). Some data on this graph is identical with that
displayed in fig. 3.5.
Intranasal administration of Timothy grass pollen allergens causes IgG1 mediated
sensitisation, which can be prevented by dexamethasone treatment
As shown before, sensitising mechanisms to Timothy grass pollen allergens in mice are
mainly mediated via IgG1 instead of IgE [123]. In previous studies, it could be proven
that this is true for respiratory sensitisation as well (data not shown). IgG1 concentration
in plasma increased throughout the duration of allergen challenges and could only be
effectively reduced by dexamethasone treatment. Additionally, the number of B220+ cells
in mediastinal lymph nodes was reduced in this treatment group, implicating a restrained
appearance of antibody-secreting plasma cells (fig.3.18).
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Figure 3.18: Plasma IgG1 and B220+ lymph node cells in the model of chronic
respiratory sensitisation. Course of plasma IgG1 levels when Timothy grass pollen
allergens were intranasally administered twice a week on two consecutive days, and B220+
mediastinal lymph node cells after 30 provocations. IgG1 levels were significantly reduced
in negative control and dexamethasone-treated group compared to positive control after 30
allergen provocations (p < 0.001, each).
Chronic respiratory sensitisation promotes the development of allergic
inflammation
In allergen challenged mice, a prominent eosinophilic inflammation was induced, displayed
as exaggerated total cell counts, granulocytes and lymphocytes as well as Th2-cytokines
in BALF (fig. 3.19). Furthermore, eosinophils massively infiltrated the peribronchial and
perivascular space. These exaggerations were not observed in dexamethasone treated mice
(fig. 3.20).
The pharmacological intervention with BPPcysMPEG started during the phase of sensiti-
sation. Treatment with the TLR-agonist in combination with IFN-γ, but also administered
alone, resulted in strong reduction of BALF eosinophils and Th2-cytokine levels, while
lymphocyte numbers were not affected (fig. 3.19). Although eosinophil counts in BALF
were markedly reduced in all TLR-agonist treated groups, this reduction was observed in
tissue after B4 treatment only (fig. 3.20).
Despite the induction of a profound allergic airway inflammation, measurement of airway
hyper responsiveness to methacholine in head-out bodyplethysmography revealed no
significant differences among the study groups (data not shown).
3.5 Intervention of chronic allergic asthma by a TLR2-ligand and IFN-γ 55
Interestingly, all treatments showed a clear reduction of CC-chemokines, either eotaxin
(CCL11) or RANTES (CCL5) (fig. 3.21).
Figure 3.19: Cellular inflammation in BALF in the model of chronic respiratory
sensitisation. Left panel displays the course of the contribution of lymphocytes, neutrophils
and eosinophils to the total cell counts in BALF, middle panel the cellular composition after
30 Timothy grass pollen extract, which is equivalent to 10 intranasal TLR-agonist and /or
IFN-γ instillations. Right: IL-4 and IL-5 levels in BALF after 30 provocations (ud= under
detection limit).
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Figure 3.20: Histology of the lung (Giemsa) and eosinophils in tissue in the
intervention of chronic respiratory sensitisation. Giemsa stained kryosections of
the distal part of the main bronchus after 30 intranasal Timothy grass pollen extract
instillations / 10 intranasal treatments with either 2 or 4 ng TLR-agonist BPPcysMPEG
in combination with 5× 103UIFN-γ (B 2/I or B 4/I, respectively), the same dose IFN-γ
without TLR-agonist, and 4 ngBPPcysMPEG (B4). Dexamethasone (Dex) treatments
were performed i.p. 18 h and 2 h before each extract provocation. All treatments started
after 10 provocations. Photographs were taken at 400x magnification. To assess allergic
inflammation in lung tissue red-stained eosinophils were counted (n=3 / group) in three
fields of view (FOV) per animal.
Figure 3.21: Eotaxin and RANTES in BALF in preventively intervened chronic
respiratory sensitisation. Both CC-chemokines were assessed after 30 intranasal extract
administrations. Significantly reduced amounts of chemotactic factors for eosinophils and
Th2-lymphocytes were found in every treatment group. (Ud=under detection limit)
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Remodelling
Massively infiltrated lung tissue as well as hyperplasia of the respiratory epithelium
was prominent in sensitised animals (figs. 3.20, 3.22, 3.23). Quantitative assessment of
collagen in whole lung homogenates did not reveal statistical differences, nor did scoring
of epithelial basement membrane thickening (data not shown).
Evaluation of histo-morphologic alterations was performed blind to the experimental
groups by an experienced pathologist (Marina Greweling, Helmholtz Centre for Infection
Research, Braunschweig, Germany) as described in section 2.1.9. Scoring of Giemsa
stained sections revealed varying amounts of peribronchial and perivascular infiltrates of
inflammatory cells. The infiltrates contained eosinophils. Mast cells were found mainly
within the epithelium. Furthermore, bronchial epithelial hyperplasia was frequently seen.
The overall severity of lesions was reduced in groups of mice treated with B2/I or B 4,
as was the score of infiltrates in B 2/I (fig. 3.23). Epithelial hyperplasia was reduced
when mice received B4. Summing up the different scores results in the total score of
remodelling, this total score was reduced in mice treated with either B 2/I or B 4.
In summary, positive controls showed clear signs of remodelling processes. Dexamethasone,
IFN-γ and 4 ng BPPcysMPEG/IFN-γ had no effect on remodelling. Such effects could be
observed in B 2 I- and B4-treatment groups.
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Figure 3.22: Localisation and quantification of collagen in lung tissue in preven-
tive intervention of chronic respiratory sensitisation. Collagen deposition in lung
kryosections was visualised by performing Azan novum stain. Covering the epithelium
of the distal part of the main bronchus, mucus (light blue) can be identified. Muscles
and reticular connective tissue is stained orange, nuclei of infiltrating inflammatory cells
brownish. Collagen appears dark blue. A thickening of the basement membrane could
not be proven. Collagen quantification of whole lung homogenates revealed no significant
differences among the groups.
Figure 3.23: Score of remodelling in the intervention of chronic respiratory
sensitisation. Giemsa-stained sections were scored for the overall severity, the amount
of inflammatory infiltrates and the grading of bronchial epithelial hyperplasia from 0 to 3,
following the criteria described in Material and Methods.
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Dexamethasone reduces CD11c+ antigen presenting cells in lung draining
mediastinal lymph nodes
In lung draining lymph nodes, an increase of CD11c+ cells could exclusively be diminished
by dexamethasone treatment (fig. 3.24). Dexamethasone additionally reduced normal
occurrence CD11c+ cells in spleen, underlining its systemic suppressive effects.
Figure 3.24: CD11c+ cells in mediastinal lymph nodes and spleen in preven-
tively intervened chronic respiratory sensitisation. Cells were quantified after FACS
analysis. In lymph nodes, CD11c+ cell counts were significantly increased, an effect not
observed in spleen. Treatment with dexamethasone reduced CD11c+ cells in both organs.
TLR-agonist, IFN-γ or both in combination influence T-cell mediated immune
responses, which leads to a reduction of allergic inflammation
Although lymphocyte counts in BALF were not altered compared to positive control,
differences in T-cell mediators could be detected. Besides the already mentioned effects
on Th2-cytokine and chemokine release into the bronchoalveolar space, IL-10 levels
were raised in untreated sensitised Pos group. No significantly different occurrence of
CD4+foxp3+ lymph node cells were observed among the groups (fig. 3.25). Therefore,
it is concluded that the beneficial effects of dexamethasone, TLR-agonist and/or IFN-γ
treatment are not mediated via the induction of tolerance.
Additionally, neither a reduction of IL-12p40, nor an increase in IL12-p70 or IL-6 was
observed (fig. 3.26). Neutrophil counts in BALF were rather reduced in the IFN-γ treated
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Figure 3.25: Regulation of the allergic response in preventively intervened respi-
ratory sensitisation. Decreased IL-10 concentrations in BALF and unaffected occurrence
of CD4+foxp3+ cells in mediastinal lymph nodes exclude an induction of tolerance. IL-10
concentrations in BALF as well as CD4+foxp3+ cells were assessed after 30 intranasal
extract provocations.
group than increased, and their contribution to cellularity of BALF was not different to
positive control (fig. 3.19). IFN-γ could only be detected in BALF in those groups, which
received an intranasal IFN-γ instillation 12 h before animals were sacrificed and lavage was
collected. No induction of IFN-γ was observed when the TLR-agonist was administered
alone (fig. 3.26). These results exclude a Th2/Th1-shift of the immune response following
TLR-agonist and IFN-γ administration.
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Figure 3.26: Cytokines in BALF in preventively intervened chronic respiratory
sensitisation. Th-1 related cytokine IFN-γ could only be measured in animals that received
IFN-γ applications the day before sampling. Neither a Th1-promoting ratio of IL-12p70 to
IL-12p40, nor an exaggeration of proinflammatory IL-6 concentrations were detected in the
different treatment groups (after 30 Timothy grass pollen extract provocations, ud=under
detection limit).

4 Discussion
The main results of this thesis are:
• Mouse models of airway hyper responsiveness and allergic airway inflammation
which use grass pollen allergen were developed and validated. These models reflect
human allergic asthma by mimicking the acute, sub-chronic and chronic phase of
the disease.
• Through the use of both, human relevant grass pollen allergen and confrontation
routes, resemblance of sensitisation and effector phase was clearly improved.
• The proven beneficial pharmacological intervention of airway hyper responsiveness
and allergic airway inflammation by a toll-like receptor agonists in combination with
IFN-γ is not achieved by a Th2/Th1-shift or induction of tolerance, but rather due
to a reduction of T-cell function.
4.1 Pollen allergens
Allergic diseases show high prevalence and incidence, especially in the Western world.
This might be connected to the Western life style and the impact the so called modern way
of life has on environmental factors. Pollen grains are a main source for seasonal allergens,
causing allergic disorders as rhinitis, conjunctivitis, and asthma. If the plant is stressed,
for example by air pollution, allergenicity of the pollen grains raises importantly [124].
Moreover, the allergenicity is further amplified by aggravated occurrence of particles, e.g.
diesel exhaust particles, in urban areas [125]. For allergic rhinitis, pollen is believed to
cause symptoms after contact to the nasal mucosa. However, for causing allergic asthma,
pollen grains are in fact too big in size to be inhaled to the lung and penetrate the deeper
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airways. Therefore, pollen starch granules (PSGs) are believed to be respirable allergen
particles responsible for the onset of asthma [126]. These PSGs are released under certain
climate conditions. Important factors for the generation, release and distribution of PSGs
are temperature, humidity and wind shaking [127]. The ability of PSGs to provoke a
humoral immune response has been shown in whole-pollen sensitised rats [128].
Also in the studies related to this thesis, PSGs were able to cause allergic inflammation
in mice sensitised towards grass pollen allergen. However, there still remain variances in
allergenicity of pollen grains, either due to environmental conditions, to natural biologic
variation, or to the isolation technique applied. Moreover, due to their natural origin,
a contamination of the PSG-preparation, e.g. with endotoxins, can not be excluded.
Endotoxins on the one hand can cause sepsis; on the other hand they are ligands to
toll-like receptors and therefore strong immunomodulators [129]. This makes PSGs to an
allergen source hardly standardiseable and therefore not recommended in experimental
models for pharmaceutical testings.
Another mechanism for the release of allergens located on PSGs or in the pollen cytosol
is the osmotic burst of the pollen grain after contact to the respiratory mucosa. With
this burst, not only granules and proteins are ejected, but also lipids. These lipids are
actually of biological relevance for the directional growth of pollen-tubes [130], however,
pollen grains containing these pollen-associated lipid mediators (PALMs) are per se able
to activate the mucosal membrane [131]. On DCs, prostaglandin-like compounds called
E1 phytoprostanes (PPE1) inhibit the production of IL-12 and thereby promote Th2-
responses [124]. Additionally, PALMs are chemoattractants for eosinophils [132]. The
use of pollen extract preparations containing both protein-allergens and lipids, either
for induction of allergic inflammation in sensitised mice or in particular for respiratory
sensitisation, is therefore a method highly reflecting the onset of human disease and could
be developed in this work for the acute, sub-chronic and chronic phase. In these novel
and optimised animal models, very distinct questions can be investigated, for example as
tested in this work from the field of immunomodulation, but also of desensitisation or
specific immunotherapy.
For immunotherapy, different treatment regimes are investigated, using recombinant major
allergens, e.g. of birch (rBet v1, [133]), olive tree (rOle e1, [134]) and Timothy grass (rPhl
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p5 [119]), antibodies or combination vaccines against epitopes of recombinant allergens
[135, 136]. The major allergen group 5 of Timothy grass is a RNAse involved in the
plant´s defence against infections [137]. It is believed to be locally associated with PSGs,
but also in the cytosol of the pollen grain [138, 118] and forms different isoforms and
isoallergens [139].
In models in which mice are sensitised i.p. and treated by administration of recombinant
allergens, allergic symptoms induced by extract provocations were alleviated. This was due
to an induction of immunosuppression, mediated via Th3 or regulatory T-cells [133, 140].
In this thesis, continued extract challenges in the chronic model of i.p.-sensitised mice
also led to an attenuation of allergic inflammation, in contrast to animals that were only
sensitised by the respiratory route, i.e. by continued extract administrations. Therefore,
induction of tolerance might partly be a mechanism induced by systemic sensitisation, and
possibly not exclusively related to desensitisation with recombinant major allergens. The
question concerning the effect that could be observed by administration of recombinant
protein in the model of chronic respiratory sensitisation remains.
4.2 Mouse models of asthma and allergic airway
inflammation
4.2.1 Identification of susceptible mouse inbred lines
The susceptibility to induction of asthma-like phenotypes is clearly related to the genetic
background of the mouse inbred strains used [141]. BALB/c and A/J mice are particular
susceptible for induction of long lasting allergic inflammation in the lung, while airway
hyper responsiveness was not detected [122]. The susceptibility has been described in the
following ranking: BALB/c > C57/BL6 > CBA. Possibly, this is due to differences in
eosinophil survival [142].
As a prerequisite to develop improved mouse models, the susceptibility of different
inbred mouse strains to sensitisation towards Timothy grass pollen allergens was tested.
Estimation of the ability to reflect allergic inflammation, i.e. raised eosinophil counts, but
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only moderate increase in neutrophils, revealed the following order: A/J > BALB/c >
C57/BL6 > CBA/J. However, as shown before [122], even in this study airway hyper
responsiveness in A/J mice could not be measured, and the acute, sub-chronic and chronic
model was established in BALB/c.
4.2.2 Development of a protocol to induce symptoms of acute and
chronic asthma
Acute models of allergic asthma are useful tools in basic and pharmaceutical research
[143]. These models provided important insight into mechanisms, cells and mediators
contributing to establishment and maintenance of allergic asthma. Especially pharma-
ceutical intervention processes during the effector-phase of the allergic reaction can be
investigated in acute-phase models, e.g. prevention of eosinophil invasion of eosinophils
into the lung by agonisation and antagonisation of the chemokine receptor 3 (CCR3)
[144, 145]. In the acute model of allergic asthma developed in this work, all important
requirements to an acute asthma model could be fulfilled, as there are an impressive
induction of allergic inflammation depicted as raised eosinophil counts and Th2-cytokine
levels in BALF, and an airway hyper responsiveness to unspecific stimuli. In this model,
dexamethasone as a standard drug in asthma therapy shows comparable effects as in
patients. This underlines the possibility to influence asthma parameters in this model
and stresses the high similarity to human acute allergic asthma. Moreover, through the
use of an allergen relevant to humans, very distinct questions can be answered in this new
model, e.g. from the field of specific immune therapy to Timothy grass pollen allergens.
In recent years, limitations of so called acute asthma models became more and more
prominent and the need of chronic models emerged to deliver new opportunities to test
efficacy of pharmacological intervention. Acute models are not always able to answer
pharmacological questions: for example, chronic inflammation could be inhibited by
cytosolic phospholipase A2 inhibitors, an effect which was not hinted at during the acute
status [146]. Additionally, the beneficial effects of the cysteinyl leukotriene-receptor
blocking compound montelukast were demonstrated in a chronic model. Montekulast-
treatment led to a decrease in inflammation, reduction of IL-4 and IL-13 mRNA in lung
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and BALF proteins. It also influenced fibrosis, mucus plugging, and smooth muscle
hyperplasia [147], symptoms which can only be investigated in chronic models. This
emphasises an important difference between the chronic and acute status: the ability to
reflect remodelling processes. In chronic models, structural changes even persist after
cessation of allergen challenges, uncoupled from inflammation [36, 34, 32].
However, although innovative these new chronic models described in the literature also
have to face obstacles and limitations. Frequently, prolonged allergen challenges after
sensitisation end in induction of tolerance [112], and resolution of eosinophilic inflammation
[148], despite the fact that eosinophil viability factors are in fact increasing [110, 51, 52].
Also in the i.p.-model of sub-chronic allergic inflammation developed in this thesis, in
which recombinant grass pollen allergen-sensitisations and extract challenges were set up,
absolute eosinophilia in BALF decreased in sensitised mice after 22 provocations. Still
there were significant enhancements compared to sham-sensitised mice at every time point,
though. In this model, very rapidly a severe eosinophilic inflammation was induced, and
severe histological alterations were observed. However, although dexamethasone controls
showed a steady state level of inflammation, resolution of eosinophilia in positive controls
resulted in the loss of a clear pharmacological treatment effect. These finding limits the
model to a sub-chronic phase, i.e. read-out after ten provocations. Therefore, the model
of respiratory sensitisation seems to be better applicable in pharmacological testing.
These limitations of chronic models do not evolve in protocols which use human relevant
allergens, as for example timothy grass or house dust mite extract [115], and further
on abandon the use of an adjuvant as in the chronic model developed in this thesis.
However, an airway hyper responsiveness was not observed in this model. Although
this limits the model for pharmacological testings, this finding might be an additional
point closer to human pathology. From longitudinal studies it is implicated that the
manifestation of all asthma related symptoms is a long lasting-process [149]. In a 15-week
protocol of intranasal allergen extract administration, remodelling processes as for example
epithelial hyperplasia and a constantly increasing eosinophilic inflammation could clearly
be reflected. Supposably, airway hyper responsiveness might develop at a later time point.
This assumption is supported from human studies, in which remodelling processes seem
to occur long before clinical symptoms are recognised [150].
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Importantly, this model also reflects allergy mechanisms in patients more thoroughly,
concerning the human relevant allergen source, route of sensitisation, and comparable
therapeutic effects of dexamethasone. Therefore, this innovative model was set into the
focus of this work to investigate immuno-modulatory effects of TLR2-agonisations in
chronic asthma.
4.3 Pharmacological intervention of allergic asthma
4.3.1 Dexamethasone in acute and chronic asthma
Dexamethasone is a standard therapeutic in patients with allergic asthma. For phar-
macological studies in mice, it serves as a positive treatment control, to prove that the
model is per se manipulable. The expected effects of dexamethasone was observed in
an acute-phase, sub-chronic and chronic model in this thesis. However, even if in the
acute model of Timothy grass pollen induced allergic asthma preventive actions could be
shown, a preventive, i.e. long lasting, treatment with dexamethasone might bear more
disadvantages than advantages for the patient because of the systemic immunosuppressive
action of this drug.
In chronic respiratory sensitisation dexamethasone ameliorated inflammatory parameters,
an observation that agrees with other studies [151, 33]. In allergic asthma, an exaggerated
recruitment of CD31hiLy-6Cneg bone marrow precursor cells is the prerequisite to a massive
increase of DCs in mediastinal lymph nodes, as well as of eosinophils and DCs in the lung
[152].
It is hypothesised that a reduction of CD11c+ cells due to dexamethasone treatment [153]
in this model is one mechanism leading to less lymphocyte activation and inflammation,
depicted in reduced chemokine and cytokine levels, but also to a decrease of inflammatory
cells in BALF and lung tissue. Moreover, the reduction of T-cell cytokines, responsible
for so called isotype-switching, and the diminished number of B220+ cells, results in low
plasma IgG1.
Remodelling processes were not affected by dexamethasone-treatment in this model, a
phenomenon frequently described in literature [154]. Moreover, the increased deposition
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of collagen during remodelling processes is assumed to enforce dexamethasone tolerance
[155]. However, effects of dexamethasone on remodelling seem to dependent strongly on
the dose administered: high doses are able to reduce at least some features of remodelling,
while low doses can act on infiltration of the lung [156].
On the other hand, dexamethasone also prevents the development of endogenous bal-
ancing mechanisms, e.g. the induction of tolerance, and therefore plays a dual role in
therapy of allergy [70]. This prevention of tolerance was also shown in this work, as
decreased concentrations of immuno-modulating IL-10 in BALF, and unaltered occurrence
of regulatory T-cells in mediastinal lymph nodes.
4.3.2 Immuno-modulation of allergic asthma by TLR2-agonisation
The rationale for immuno-modulation by toll-like receptor agonist is delivered by the so
called hygiene hypothesis [3, 4, 5]. This hypothesis relates the increasing prevalence and
incidence of allergic diseases in the Western world with a cease in Th1-immune responses
inducing triggers especially during early childhood. For example, bacterial infections are
reduced due to a less frequent direct confrontation to bacteria, but also due to a decrease
in the number of siblings [6, 7]. In current opinion allergic asthma can be caused by
an imbalance of the Th1/Th2 axis. From this observations, a variety of experimental
intervention strategies were developed, some of them already starting during pregnancy
[157] or in newborns [158]. These strategies set the TLR4-ligand endotoxin into the scope
of investigations to induce Th1-responses, ignoring the risk of inducing sepsis. Moreover,
protection against allergy is more likely mediated via TLR2 than via TLR4 [80], which
make TLR2-agonists a promising approach in immuno-modulation.
Because dendritic cells express toll-like receptors, immuno-modulation with TLR-agonists
can causatively influence allergic diseases [159]. Dendritic cells are believed to be key
players in immune responses, in sensitisation [160] but also in maintenance of allergy [12].
Dendritic cells resting in lung tissue favour a Th2-type response and need to be triggered
with Th1-inducing stimuli [11]. These Th1-triggers can be delivered by synthetic toll-like
receptor agonists.
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TLR2-agonists in acute allergic asthma
Different studies using Mycoplasma-derived compounds underlined the immunomodulatory
capacity in treatment of the acute-phase of allergic disorders.
In naïve mice, administration of the TLR2-agonist MALP-2 into the airways attracts
neutrophils to the bronchoalveolar space within 24 h, underlining its ability to trigger Th1-
responses. Two to three days after instillation, macrophages become more prominent. On
macrophages, TLR2 agonists show clear activating effects [161]. After 72 h, lymphocytes
reach their maximum contribution to cellularity of BALF. These effects decayed after 10 d
[162]. Furthermore, changes in lung histology occur after MALP-2 aerosol administration,
where the area of bronchus-associated lymphoid tissue is increased. The functional
relevance of this finding remains to be investigated [163, 164].
In sensitised animals, different effects of TLR2-agonisation can be observed:
A therapeutic intervention of acute-phase allergic asthma could be achieved by intratracheal
treatment with the TLR2/6 agonist MALP-2 in combination with the Th1 cytokine IFN-
γ, which clearly reduced airway hyper responsiveness, eosinophilia and Th2-cytokines
in BALF. At the same time, neutrophils and IL-12p70 were increased [98]. Similarly,
treatment with a synthetic TLR2/1 ligand reduced cellular eosinophilic inflammation in
the BALF, Th2-cytokine levels, i.e. IL-4 and IL-5, as well as airway hyper responsiveness,
independent from IL-10 and TGF-β [99].
Additionally, TLR2/4-agonisation during allergen challenge in sensitised mice prevented
allergic asthma. When incubated with DCs, the TLR2/4-agonist induced synthesis of
IL-12 and TNF-α, which by itself induces IFN-γ production of T-lymphocytes. As a
result, eosinophils, IL-4 and IL-13 were reduced, while neutrophil counts and IFN-γ were
elevated. No increased activation of Th1-lymphocytes could be detected, though [96].
These studies point to a Th2/Th1 shift by TLR2-agonisation.
Investigations in an in vitro model of allergy demonstrated an induction of TNF-α and
IL-10 synthesis, but not IL-12, when blood derived DCs were stimulated with MALP-2
[101], highlighting the possibility to induce tolerance.
However, also the contrary effect, the induction of Th2, could be observed: TLR2/1
agonisation aggravated allergic asthma when administered during the initial phase of the
immune reaction. The type of TLR stimulation during this early phase seems to be a
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determinant for the polarisation of the adaptive immune response [100].
In this work, different time-points to intervene the manifestation of allergic asthma by
TLR2-agonisation with the MALP-2-derivate BPPcysMPEG in combination with the
Th1-related cytokine IFN-γ were investigated in acute asthma induced by Timothy grass
pollen allergens. Here, this treatment showed impressive beneficial effects on inflammation
and lung physiology. A preventive treatment started as early as before and during
sensitisation, reduced allergic inflammation and showed a clear trend to improve lung
function. But even in already sensitised mice, BPPcysMPEG/IFN-γ could influence
airway hyper responsiveness when administered before allergen challenge, and allergic
inflammation when treatment was performed after allergen confrontation. However, no
hint for a Th2 towards Th1-shift was observed: neutrophil counts were not altered to
positive controls, or were as shown in the therapeutic treatment significantly reduced
to an extent comparable to the dexamethasone effect. The mechanism of action of
BPPcysMPEG/IFN-γ-treatment was therefore investigated more thoroughly in the model
of chronic respiratory sensitisation.
TLR2-agonists in chronic allergic airway inflammation
The examples of successful immuno-modulations from acute-phase models of allergic
asthma demonstrate the various implementations of TLR2-agonisation in treatment of
acute allergic inflammation. These effects can be achieved either by shifting Th2 towards
Th1, or induction of tolerance, and rises the question of intervention effects in chronic
models.
In our chronic and sub-chronic model, the impressive reduction of parameters of allergic
inflammation were prominent, as well as the reduction of remodelling processes in the
model of chronic respiratory sensitisation after preventive treatment with the MALP-2-
derivate BPPcysMPEG. However, it was not hinted at a Th2/Th1-shift. In this study, the
numbers of CD11c+ and B220+ cells, as well as of CD4+foxp3+ cells in lymph nodes and
lymphocytes in BALF, were unaffected. Nevertheless, no induction of BALF neutrophilia
or Th1-promoting cytokines as IL-12p70 was observed and TNF-α levels were below the
lower limit of detection. Therefore, a T-cell mediated effect is hypothesised.
Effects of TLR2-ligands on T-cells have already demonstrated, for example the induction
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of CD4+cells apoptosis [165]. However, the unaffected number of lymphocytes and
the absence of both Th1- as well as Th2-inducing factors in the study related to this
thesis rises the question, if beneficial effects of BPPcysMPEG with or without IFN-γ
on chronic allergic airway inflammation are mediated by induction of an overall T-cell
anergy. This anergy seems to include Th-cells as well as regulatory T-cells. T-cell anergy
is a phenomenon observed also in orally administered immunotherapy [166], which may
once again underline the importance of TLR2-agonist and the use of human relevant
allergen sources and sensitisation routes in the model of respiratory sensitisation for
immunotherapy research.
Importantly, this probably is the first study in which TLR2-agonists were tested in a
chronic model, and thereby the first study demonstrating a reduction of remodelling
processes.
4.4 Conclusions
It was demonstrated, that symptoms resembling human bronchial asthma can be mimicked
in mouse models using human relevant Timothy grass allergens. In these models, the
acute, sub-chronic and chronic phase of allergic asthma can be reflected, as well as the
respiratory sensitisation to the allergen. Additionally, as a prerequisite for pharmacological
testing, similar treatment effects as in humans were observed by dexamethasone. In the
acute-phase model of asthma, airway hyper responsiveness could be established as a
read-out parameter. As a symptom occurring after a long-lasting process in asthmatic
patients, the absence of airway hyper responsiveness in the chronic models might underline
the patho-mechanistical similarity; however, it could also be related to mechanisms of
aging in the experimental animal.
The hygiene hypothesis relates the increasing prevalence and incidence of Th2-related
allergies to decreasing confrontation to bacterial stimuli, which would normally mod-
ulate dendritic cell function and balance the immune system towards Th1. Synthetic
Mycoplasma-derived toll-like receptor agonists are believed to be Th1-triggers; however,
this work could show that their preventive and therapeutic effect on airway hyper reactiv-
ity and allergic airway inflammation is not mediated via a Th2/Th1-shift or induction
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of tolerance, but reduction of T-cell function. This overall effect makes this approach
promising in prevention and therapy of diseases related to exaggerated T-cell responses,
as allergic asthma or inflammatory bowl disease.
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